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INTERACTIONS OF MOTOR AND NON-MOTOR SYMPTOMS 
IN PARKINSON’S DISEASE  
ROBERT D. SALAZAR 
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Major Professor:  Alice Cronin-Golomb, Professor of Psychological and Brain Sciences 
ABSTRACT 
Parkinson’s disease (PD) is characterized by motor dysfunction and multiple non-
motor symptoms. Though motor/non-motor interactions are common, the lines of 
research focusing on motor and non-motor symptoms mainly remain separate. The 
present studies assessed interactions between several motor aspects of PD (impaired gait, 
side of motor-symptom onset, tremor, motor-symptom severity) and non-motor 
symptoms (cognition, anxiety, self-perceived stigma) in non-demented individuals with 
idiopathic PD. 
Study 1 examined cognitive and motor performance during dual tasking, 
specifically executive function while walking. The impact of dual tasking on walking 
(speed, stride frequency) was greater for PD (N=19) than NC participants (N=13). The 
PD group had fewer set-shifts than NC on dual tasking, and demonstrated greater 
cognitive variability on dual tasking. 
Study 2 considered mechanisms of visuospatial dysfunction in PD (N=79) by 
assessing how side of motor-symptom onset (left versus right) and cognition (attention, 
executive function) affect spatial judgment on a dynamic line bisection task. In contrast 
to a rightward-biased parietal-neglect pattern, the PD group showed a leftward bias that 
 vii 
occurred when attention was directed to the left side of space, regardless of side of onset. 
The extent and variability of bias correlated with frontally-mediated neuropsychological 
performance for PD but not NC (N=67). Both results suggested frontal-attentional rather 
than parietal-neglect mechanisms of spatial bias. 
Study 3 assessed how motor symptoms contribute to self-reported anxiety on the 
Beck Anxiety Inventory (BAI). Factor analysis identified a five-item PD motor factor, 
which correlated with motor-symptom severity and mediated the difference on BAI total 
scores between PD (N=100) and NC (N=74). Removal of the motor-factor items (e.g., 
“hands trembling”) significantly reduced BAI scores for PD relative to NC and reduced 
the size of the correlation between the BAI and motor-symptom severity. 
Study 4 examined the contributions of motor and non-motor symptoms to self-
perceived stigma in PD (N=362). Contrary to expectations, perceived stigma was not 
predicted by motor symptoms but rather by depression and, for men only, by younger 
age. 
These studies provide insight into interactions that occur between motor and non-
motor symptoms in PD in multiple aspects of daily function, highlighting potential 
avenues for future research and intervention.  
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CHAPTER 1:  GENERAL INTRODUCTION 
Parkinson’s disease (PD) is traditionally considered a motor disorder with 
hallmark features such as tremor, rigidity, bradykinesia, and postural instability (Massano 
& Bhatia, 2012). Although these motor symptoms are central to the diagnostic criteria for 
PD and are often the focus of treatment approaches (Rodriguez-Oroz et al., 2009), PD is 
also characterized by a host of non-motor symptoms, some of which may predate the 
onset of motor symptoms (Chaudhuri, Healy, & Schapira, 2006; Chaudhuri, Odin, 
Antonini, & Martinez-Martin, 2011), and which have a major impact on quality of life 
(Martinez-Martin, Rodriguez-Blazquez, Kurtis, & Chaudhuri, 2011). Recent research has 
provided substantial contributions to the characterization and understanding of PD non-
motor symptoms, and has described PD-related problems with cognition, mood, vision, 
and sleep, among many other symptoms (Cronin-Golomb, 2010, 2013). To date, the line 
of research focusing on motor symptoms mainly is separate from the line of research 
focusing on non-motor symptoms. Without an understanding of the interaction between 
motor and non-motor symptoms, the conceptualization of PD remains incomplete. The 
purpose of this project was to investigate the interaction of motor and non-motor 
symptoms and their impact on function in PD.  
 
Neuropathological Process of PD | Cognitive, Motor, and Non-Motor Consequences 
The neuropathological process of PD is complex and includes cortico-cortical and 
cortico-subcortical dysfunction. Motor symptoms arise from the death of dopaminergic 
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neurons in the substantia nigra. Dopamine depletion affects the feedback processing 
system of the basal ganglia, which subsequently disrupts cortical and subcortical 
networks (Alexander, DeLong, & Strick, 1986; Middleton & Strick, 2000; Monchi et al., 
2004), and ultimately produces a cascade of motor and non-motor deficits, including in 
cognition (Gittis & Kreitzer, 2012; Parks, Levine, & Long, 1998; Soghomonian, 2016; 
Surmeier, Carrillo-Reid, & Bargas, 2011).  
 
Non-Motor Symptoms and Neural Dysfunction in PD 
Functional magnetic resonance imaging (fMRI) studies testify to the complexity 
of the relation of brain function and cognition in PD. When mentally manipulating 
information (i.e., working memory), individuals with PD and executive impairment 
showed an underactivation of the caudate nucleus, dorsolateral prefrontal, and 
ventrolateral prefrontal cortex compared to those with PD without executive impairment 
(Lewis, Dove, Robbins, Barker, & Owen, 2003). Though individuals with PD and a 
healthy control group both exhibited activation of bilateral frontal-parietal networks on 
an object working memory task, the activation was less in the PD than in the control 
group (Caminiti, Siri, Guidi, Antonini, & Perani, 2015). Individuals with PD showed less 
activation of the inferior orbitofrontal cortex compared to healthy control adults, and this 
related to poorer verbal recognition memory (Lucas-Jiménez et al., 2015). Compared to 
healthy control adults, those with PD exhibited reduced activation of the right insula, left 
putamen, bilateral caudate, and right hippocampus and increased activation of the right 
dorsolateral prefrontal and posterior parietal cortices on a visuospatial task (Caproni et 
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al., 2014). In regard to the hippocampus, there is evidence for functional change in non-
demented individuals with PD (Calabresi, Castrioto, Di Filippo, & Picconi, 2013). 
Greater diffusion in the hippocampus in PD compared to healthy control participants, as 
measured with diffuse tensor imaging, has been found to be related to poorer verbal 
memory performance (Carlesimo et al., 2012). Studies of functional connectivity have 
demonstrated how PD affects major networks such as the default mode network (DMN), 
salience network (SN), and central executive network (CEN). Relative to healthy control 
adults, individuals with PD showed less coupling of the SN and CEN and greater 
coupling of the CEN and DMN (Putcha, Ross, Cronin-Golomb, Janes, & Stern, 2015). 
For healthy control adults but not for those with PD, functional coupling between the 
DMN and SN was significantly correlated with executive function, verbal memory, and 
psychomotor processing speed (Putcha, Ross, Cronin-Golomb, Janes, & Stern, 2016).  
Certain of the non-motor symptoms (e.g., changes in olfaction, mood, sleep, 
general arousal) may appear in prodromal PD (before motor symptoms), as noted above, 
presumably resulting from brainstem pathology that predates the appearance of pathology 
in the substantia nigra. The neurodegenerative process of PD initially targets the lower 
brainstem, resulting in autonomic, sensory, and psychiatric symptoms. Diagnosis of PD 
occurs once the pathology has ascended to the midbrain, at which point motor symptoms 
develop. As the pathology gradually progresses to the neocortex, higher-order cognitive 
dysfunction emerges (Braak et al., 2006; Braak et al., 2003).  
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Motor Symptoms and Neural Dysfunction in PD 
Regarding the motor symptoms, neuropathological differences appear to underlie 
different motor profiles of PD. Motor symptoms are commonly classified as tremor 
dominant (TD) and non-tremor dominant (NTD). Compared to TD, NTD have been 
found to have greater dopaminergic loss at autopsy, specifically in the internal globus 
pallidus (GPi) (Rajput et al., 2008). Poorer dopaminergic uptake in the putamen, as 
measured by single photon emission computed tomography (SPECT), relates to the 
extent of rigidity and hypokinesia, but does not relate to tremor (Spiegel et al., 2007). 
Compared to TD, individuals with postural instability and gait disorder (PIGD) 
demonstrated metabolic reductions in the caudate and inferior parietal lobule on 
fluorodeoxyglucose positron emission tomography (FDG-PET) (Zhang et al., 2016). 
Tremor severity relates to reductions in serotonin receptors in the raphe nuclei (Doder et 
al., 2003) and individuals with TD motor symptoms have a greater reduction of serotonin 
receptors than those with akinetic-rigid PD (Loane et al., 2013; Politis & Niccolini, 
2015). Reductions in serotonin transporter availability in the raphe nuclei have been 
reported to be related to tremor amplitude, rest tremor constancy, and tremor severity, 
and those with TD had significantly lower serotonin transporter availability than those 
with NTD (Qamhawi et al., 2015). These motor symptom subtypes are also associated 
with differential prognostic outcomes, including in regard to non-motor symptoms. Those 
with dominant non-tremor symptoms have a worse prognosis, with more extensive 
problems in perception and cognition (Seichepine et al., 2011; Selikhova et al., 2009; 
Williams-Gray et al., 2009) including tendency to dementia, and poorer quality of life 
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(Appleman, Stavitsky, & Cronin-Golomb, 2011). 
 
Side of Motor Symptom Onset in PD 
Side of motor symptom onset is another common motor symptom classification 
with specific neuropathological correlates. Initial motor symptom presentation on the 
right side of the body (RPD) reflects predominant dysfunction of the left striatum and its 
connections to the cortex; initial motor symptom presentation on the left side of the body 
(LPD) reflects predominant dysfunction of the right striatum and its connections to the 
cortex. Consequently, individuals with RPD tend to experience non-motor symptoms 
associated with left hemispheric dysfunction, whereas those with LPD primarily 
experience functional deficits associated with right hemispheric dysfunction (Verreyt, 
Nys, Santens, & Vingerhoets, 2011). Specifically, there are LPD-RPD differences in 
cognition (Amick & Grace, 2006; Schendan, Amick, & Cronin-Golomb, 2009; 
Seichepine, Neargarder, Davidsdottir, Reynolds, & Cronin-Golomb, 2015), visual 
perception (Davidsdottir, Wagenaar, Young, & Cronin-Golomb, 2008), visual scanning 
(Clark, Neargarder, & Cronin-Golomb, 2010), visual attention (DeGutis et al., 2016; 
Laudate, Neargarder, & Cronin-Golomb, 2013), line bisection (Lee, Harris, Atkinson, & 
Fowler, 2001), emotion recognition (Clark, Neargarder, & Cronin-Golomb, 2008), gait 
veering (Davidsdottir et al., 2008; Ren et al., 2015), sleep (Stavitsky et al., 2008), mood  
(Bogdanova & Cronin-Golomb, 2012; Fleminger, 1991; Leentjens, Lousberg, & Verhey, 
2002; Tom & Cummings, 1998; Tomer & Aharon-Peretz, 2004; Tomer, Levin, & 
Weiner, 1993), and motivation (Bogdanova & Cronin-Golomb, 2013; Leentjens et al., 
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2002). This neuropathological laterality persists throughout the disease course, even after 
the striatum is bilaterally affected (Antonini et al., 1995; Booij et al., 1997). 
 
Functional Consequences of Motor and Non-Motor Symptoms in PD 
The combined burden of progressive motor and non-motor symptoms in PD 
imposes notable limitations to activities of daily living and quality of life. Unlike other 
major neurodegenerative diseases (e.g., Alzheimer’s disease), an individual with PD may 
manage the disease for decades after diagnosis, and may also retain insight into their 
daily challenges. Accordingly, the ability to preserve independence is critical to 
promoting quality of life in PD.  
Because of the complexity of the disease course, recognition of non-motor 
symptoms (and their subsequent interaction with motor symptoms) may easily go 
unrecognized and untreated (Chaudhuri & Odin, 2010). There are a host of PD non-motor 
symptoms that occur throughout all stages of the disease, including pre-diagnosis (for 
review see (Chaudhuri et al., 2006; Poewe, 2008). These symptoms have a substantial 
contribution to quality of life and occur in a majority of individuals with PD (up to 98%); 
(Barone et al., 2009). Many non-motor symptoms are not ameliorated by standard 
psychopharmacological treatments of motor symptoms (e.g., L-dopa), and as the disease 
progresses, the non-motor symptoms become a prominent source of distress and 
disability (Hely, Morris, Reid, & Trafficante, 2005; Politis et al., 2010). Non-motor 
symptoms have a stronger contribution to quality of life than motor symptoms (Martinez-
Martin et al., 2011) and are associated with increased disease duration and severity 
7 
 
(Martinez-Martin et al., 2009). Men and women experience non-motor symptoms 
differently (Martinez-Martin et al., 2012; Miller & Cronin-Golomb, 2010), and women 
with PD experience more non-motor symptoms than men (Martinez-Martin et al., 2009). 
The impact of motor and non-motor PD symptoms in nearly all aspects of daily life is a 
defining feature of this disease. A recently-developed scale of non-motor symptoms of 
PD (Chaudhuri et al., 2007) assesses 9 domains – cardiovascular, sleep/fatigue, 
mood/cognition, perceptual problems, attention/memory, gastrointestinal, urinary, sexual 
dysfunction, and miscellaneous (pain, taste/smell, weight change, sweating). The motor 
aspects of PD impact instrumental activities of daily living, including speech, feeding 
(handling utensils, chewing, swallowing), dressing, hygiene, handwriting, and mobility 
(e.g., walking, rising from a chair or from bed) (Goetz et al., 2008). Together the motor 
and non-motor symptoms of PD may affect nearly all aspects of life.  
In addition to the pervasiveness of these symptoms, there is great heterogeneity in 
presentation. For example, some individuals with PD may experience minimal tremor 
symptoms, but may experience substantial problems with gait and balance (e.g., postural 
instability and gait disorder), while others may predominantly experience tremor 
symptoms. The heterogeneity of these motor symptoms, and their different disease 
trajectories, have been a topic of extensive investigation (Berg et al., 2014; Selikhova et 
al., 2009; Thenganatt & Jankovic, 2014). Similarly, non-motor symptoms do not present 
uniformly across all individuals with PD. For example, the constellation of PD symptoms 
vary by age of disease onset, side of motor symptom presentation, dominant motor 
symptom, gender, disease duration, and disease severity; the interaction of these 
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symptoms are strikingly complex and understudied.  
The heterogeneity of PD symptoms, and their pervasiveness throughout the 
disease course, presents clinicians and researchers with multiple opportunities to identify 
and describe the nature of debilitating PD symptoms, and to develop interventions for 
them. To date, PD symptoms have been dichotomized as either motor or non-motor 
symptoms, with comparatively little work considering how the interaction of these 
symptoms affects independence and quality of life (Muller, Assmus, Herlofson, Larsen, 
& Tysnes, 2013). By considering the interactions of motor and non-motor symptoms, 
new opportunities may arise for conceptualizing and treating PD symptoms.  
 
Specific Aims and Hypotheses 
In the series of studies described here, emphasis was placed on common 
functional challenges that result from interactive PD motor and non-motor symptoms. 
Regarding motor symptoms, gait, side of motor symptom onset, and visibility of motor 
symptom (e.g., tremor) were considered. The focus of non-motor symptoms was on 
cognition (executive function, visuospatial cognition) and mood (anxiety, self-perceived 
stigma), each of which contributes substantially to quality of life (Barone et al., 2009; 
Klepac, Trkulja, Relja, & Babić, 2008; Leroi et al., 2011; Muslimović et al., 2008; 
Rahman, Griffin, Quinn, & Jahanshahi, 2008; Schrag, 2006; Schrag, Jahanshahi, & 
Quinn, 2000). The following specific interactions were assessed, as justified and 
described in the sections below: 1) executive function and gait; 2) visuospatial cognition 
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and side of motor symptom onset; 3) overlapping anxiety and motor symptoms such as 
tremor; and 4) self-perceived stigma, depression, and motor symptom subtype. 
 
Study One:  Dual Tasking in Parkinson’s Disease: Cognitive Consequences While 
Walking 
There is little PD research on how cognition is impacted by dual tasking—that is, 
performing a cognitive task at the same time as a motor task (walking). Instead, the 
primary focus of dual-tasking research is on resulting motor deficits, such as reduction of 
walking speed. Study 1 assessed the interaction of motor and non-motor performance 
during dual tasking, specifically measuring how executive function is affected by 
concurrent walking. Because PD is associated with both cognitive and motor dysfunction, 
a dual cognitive-motor task was expected to significantly impact cognitive function as 
well as walking. Executive function was indexed by set-shifting ability, which is 
commonly affected in PD and may be an important marker of problems with dividing 
attention and managing the multiple demands of locomotion. Dual tasking was expected 
to have a relatively greater impact on set-shifting performance than on aspects of walking 
(speed, stride length, stride length). Further consideration was placed on whether PD 
performance was marked not only by reduced output (i.e., a lower mean score), but also 
by less stability or greater variability; the hypothesis was that response variability in PD 
would be markedly impacted by dual tasking. 
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Study Two: Spatial Bias in Parkinson’s Disease: Contributions of Attentional and 
Executive Dysfunction 
Spatial dysfunction is a non-motor symptom of PD that is usually attributed more 
to right- than left-hemisphere dysfunction, though much uncertainty remains regarding its 
primary mechanism. Study 2 assessed potential mechanisms by considering how motor 
and non-motor symptoms affect dynamic spatial judgment. Two hypotheses were 
contrasted – a frontal-executive hypothesis and a parietal-neglect hypothesis. The frontal-
executive hypothesis suggested that difficulties in spatial judgment are the consequence 
of dysfunctional cognitive processes associated with the frontal lobes, such as attention 
and executive function. The ability to coordinate and execute the multiple aspects of 
dynamic spatial judgment (perception, visuomotor control, decision making) would be 
affected by the attentional and executive deficits that are common in PD, even at early 
disease stages (Miller, Neargarder, Risi, & Cronin-Golomb, 2013). Relative to healthy 
adults, individuals with PD would be expected to perceive a midline that is significantly 
farther from true center. The extent of deviation in PD spatial judgment (bias) would 
correlate with performance on neuropsychological measures of attention and executive 
function, such that poorer attention and executive function would relate to poorer spatial 
judgment. 
If spatial bias is driven by attentional-executive deficits, two patterns of 
performance would be expected that differ from consistent neglect of a specific hemifield 
(that is, traditional hemineglect) on line bisection tasks: 1) Spatial judgment in PD would 
be affected by initial location of the stimulus (that is, placing a landmark to the right vs. 
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left of the center of the stimulus line). Instead of traditional hemineglect, a spatial bias 
would be introduced by orienting attention to either the right or left side of space. If 
attention were oriented rightward, PD would be prone to neglect the left side of the 
stimulus line; if attention were oriented leftward, the right side would be neglected. 2) 
Spatial judgment in PD would be characterized by greater variability in responses 
compared to healthy adults. Inconsistency in spatial judgment would argue against the 
existence of hemineglect, and would instead highlight inconsistencies in coordinating and 
executing the demands of spatial judgment. Because frontal-type impairments occur 
regardless of side of PD onset, the correlations and performance patterns should be 
similar in LPD and RPD.  
The parietal-neglect hypothesis predicted neglect of the left side of space relative 
to the right side of space, as is seen in individuals with right-parietal damage due to 
stroke (Beis et al., 2004; Saj, Fuhrman, Vuilleumier, & Boroditsky, 2014; Verdon, 
Schwartz, Lovblad, Hauert, & Vuilleumier, 2009). In this case, there would be a 
consistent rightward shift in spatial judgement dependent on motor symptom laterality; 
specifically, those with LPD, but not RPD, would exhibit a rightward shift in spatial 
judgment, reflecting right-parietal dysfunction in LPD specifically. For LPD, spatial bias 
would increase when initial placement of the landmark was on the right side of center 
(i.e., enhancing neglect of the left side of the line), whereas initial landmark placement to 
the left would reduce the extent of bias (i.e., minimizing neglect of the left side of the 
line). Those with LPD would not misjudge the left side of space, but instead would 
perform comparably to a healthy control group.  
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Study Three: The Impact of Motor Symptoms on Self-Reported Anxiety in Parkinson’s 
Disease 
Study 3 assessed how motor symptoms contribute to self-reported mood, using 
the Beck Anxiety Inventory (BAI), a common measure of anxiety. A factor analysis 
assessed whether PD motor symptoms (e.g., hands trembling, shaky, unsteady) grouped 
together. Further analyses assessed the impact of these motor symptoms on the BAI, with 
the expectation that motor symptoms would elevate self-reported anxiety scores. Support 
of the primary hypotheses – that motor symptoms group together on the BAI and 
significantly influence BAI scores – would suggest that commonly used anxiety scales 
that were not specifically designed for a PD population may be problematic, and hence 
encourage the use of PD-specific anxiety measures. A secondary hypothesis considered if 
BAI scores were influenced by overall motor severity or by specific motor symptoms 
such as tremor; the BAI score of individuals with tremor motor symptoms that closely 
resemble BAI items (e.g., hands trembling, shaky) may be more affected than those with 
non-tremor motor symptoms. 
 
Study Four: Predictors of Self-Perceived Stigma in Parkinson’s Disease 
Self-perceived stigma in PD is characterized by shame toward the physical 
manifestations and functional limitations of the disease. Traditional PD treatments aim to 
mitigate motor dysfunction but overlook an individual’s subjective response to the 
disease. To date, the investigation of self-perceived stigma in PD has been mostly 
qualitative, which places major limitations to the understanding and treatment of stigma. 
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Study 4 assessed the relation between disease-specific motor symptoms and self-
perceived stigma, while considering how demographic and non-motor symptoms affect 
this relation. Age, gender, motor symptom subtype, and depression were expected to 
influence the relation between PD and self-perceived stigma. With respect to 
demographic predictors of stigma, those that most strongly interact with social norms 
(e.g., societal emphasis on the appearance of women and the vigor/competence of youth) 
would be expected to drive experiences of self-perceived stigma. Regarding disease-
related predictors of stigma, motor symptoms that are more visible (e.g., tremor, 
dyskinesia, facial masking) would be more important predictors of stigma than the less 
visible symptoms (such as axial rigidity). In regard to non-motor symptoms, there was 
specific interest in the contribution of depression to stigma because of the prevalence and 
pervasive impact of depression on individuals with PD.  
 
Significance 
As is clear from the discussion above, motor and non-motor symptoms of PD, 
though classified differently and subject to different (and unequal) treatment, are not 
independent of each other. Although the traditional classification of PD as a “motor” 
disorder may promote emphasis on motor symptoms and overlook the importance of non-
motor symptoms, the combination of motor and non-motor symptoms may have the most 
critical impact on the functional outcomes. For example, gait dysfunction commonly 
occurs in PD and is considered a motor symptom (e.g., postural instability, bradykinesia). 
Many individuals with PD also have problems with vision, visuospatial function, and 
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cognition, which contribute to gait disturbance (Davidsdottir et al., 2008; Lin et al., 2014; 
Nantel, McDonald, Tan, & Bronte-Stewart, 2012; Ren et al., 2015; Young et al., 2010). 
In regard to the motor symptoms, the observability of the symptom tends to relate to the 
perceived importance; tremor is likely to lead an individual to seek medical treatment 
sooner than bradykinesia (slowness of movement), which is another cardinal motor sign 
of PD, and both of these may be treated more aggressively by a neurologist than are the 
less obvious symptoms of cognitive or visual dysfunction, anxiety, or depression. Failing 
to consider the contribution of visual or visuospatial symptoms to driving and walking 
would limit the assessment of these common PD symptoms.  
Considering motor symptoms apart from relevant non-motor symptoms, or indeed 
considering any single symptom in isolation from the others, even within the categories 
of motor vs. non-motor symptoms, may promote oversights in research and treatment. 
Understanding how motor and non-motor symptoms interact to contribute to functional 
outcomes may lead to more comprehensive assessments and treatments of PD, enhancing 
quality of life in this disorder. The present studies promote a framework for scientists and 
clinicians that considers the entire symptom profile of PD. Though this project presents 
four important motor-non-motor intersections, many more intersections certainly exist, 
and are worthy of further investigation. The neuropathology of PD results in a 
widespread set of motor and non-motor symptoms and tremendous heterogeneity from 
person to person; this complex symptomatology of PD may be the primary deterrent to 
adopting an inclusive framework for researching, assessing, and treating PD symptoms. 
Nonetheless, moving beyond a static conceptualization of PD as strictly a “motor 
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disorder” and considering the full spectrum of debilitating PD symptoms is an important 
step to improving care for individuals with this disease. Taken together, these studies 
propose a dynamic approach to conceptualizing PD that contrasts with the static, 
categorical approaches that are ever-present in research and treatment settings.  
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CHAPTER 2:  STUDY ONE | DUAL TASKING IN PARKINSON’S DISEASE: 
COGNITIVE CONSEQUENCES WHILE WALKING 
© American Psychological Association, 2017. This paper is not the copy of record and 
may not exactly replicate the authoritative document published in the APA journal. 
Please do not copy or cite without author's permission. The final article is available, upon 
publication, at: https://psycnet.apa.org/doi/10.1037/neu0000331 
 
Introduction 
Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms 
that present challenges to activities of living and quality of life. A prominent example of 
the interaction of motor and nonmotor symptoms is in the domain of walking. Beginning 
with the motor symptoms, PD-related gait abnormalities include slow walking speed, 
short strides, propulsion, retropulsion, shuffling steps, reduced or absent arm swing, and 
rigidity in trunk movements (Rochester et al., 2004; Van Emmerik, Wagenaar, 
Winogrodzka, & Wolters, 1999; Winogrodzka, Wagenaar, Booij, & Wolters, 2005), with 
some individuals also experiencing freezing of gait (Davidsdottir, Cronin-Golomb, & 
Lee, 2005; Giladi et al., 2001). The severity of such impairments ranges from mild (i.e., 
“preclinical gait syndrome”; Panyakaew & Bhidayasiri, 2013) to debilitating (reviewed in 
(Ebersbach, Moreau, Gandor, Defebvre, & Devos, 2013) and is associated with increased 
risk of physical harm from falls (Grimbergen, Munneke, & Bloem, 2004; Rochester et al., 
2004; Wood, Bilclough, Bowron, & Walker, 2002; Woollacott & Shumway-Cook, 2002). 
Impairments of walking accordingly impose marked limitations to mobility and quality of 
life (Bloem, Hausdorff, Visser, & Giladi, 2004; Grimbergen et al., 2004; Martinez-
Martin, 1998). 
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Among the nonmotor symptoms, cognitive impairments are common in PD and 
interact with walking and other motor symptoms. Even early in the disease course, 
disruptions to frontal-striatal circuitry result in attentional and executive dysfunction 
(Miller et al., 2013). Executive function, including set-shifting, seems especially 
important to walking in PD. Set-shifting deficits occur in the early stages of PD (Cronin-
Golomb, Corkin, & Growdon, 1994) and are related to disrupted frontal-striatal circuitry 
(Monchi et al., 2004). Such deficits limit the ability to manage complex task demands, 
and may affect locomotion by disrupting the ability to simultaneously execute cognitive 
and motor plans, and to flexibly respond to changes in the environment. For example, 
impaired set-shifting capacity has been found to be associated with reductions in gait 
speed and stride length (Plotnik, Dagan, Gurevich, Giladi, & Hausdorff, 2011). In PD 
with gait freezing, the extent of freezing correlated with set-shifting scores (Naismith, 
Shine, & Lewis, 2010) and with lower scores on a number of executive function 
measures (Amboni, Barone, & Hausdorff, 2013; Amboni, Cozzolino, Longo, Picillo, & 
Barone, 2008). Greater stride-time variability on dual tasking was associated with lower 
scores on a Stroop interference task (Yogev et al., 2005). Dual-tasking studies of PD have 
identified several deleterious changes in gait that are elicited by concurrent cognitive 
challenge (i.e., cognitive load), including slower walking speed (Yogev-Seligmann, 
Giladi, Gruendlinger, & Hausdorff, 2013), increased stride width (Panyakaew & 
Bhidayasiri, 2013), increased gait variability (Hausdorff, Balash, & Giladi, 2003; Yogev 
et al., 2005), shorter step length (Rochester et al., 2004), postural instability (Marchese, 
Bove, & Abbruzzese, 2003; Rochester, Galna, Lord, & Burn, 2014), more steps and 
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increased cadence during turns (Spildooren et al., 2010), and poorer bilateral inter-limb 
coordination (Plotnik et al., 2011; Plotnik, Giladi, & Hausdorff, 2009).  
 As shown by the studies above, the overwhelming emphasis of dual-tasking 
(cognitive-motor) assessment in PD is on motor output (i.e., walking). That is, the dual-
task cost is to motor function. Understanding of the effects of dual tasking in PD is 
incomplete, however, without also considering its cost to cognition. The use of dual-
tasking experimental paradigms is based upon the premise that attentional resources are 
limited; simultaneous tasks compete for this finite store of attention. Commonly cited 
systems for executing multiple tasks include the supervisory attentional system, the 
executive control network, the central executive, and top-down attentional control; 
collectively these constructs can be subsumed under the category of executive control 
(Daffner & Willment, 2014), which is dependent upon cortical-subcortical circuitry that 
is disrupted in PD (Putcha et al., 2015; Rowe et al., 2002; Shine, Halliday, Naismith, & 
Lewis, 2011; Shine et al., 2013; Tessitore, Amboni, et al., 2012).  
Most clinical and research dual-tasking assessments emphasize the impact of 
cognitive load on motor function, presumably since deficient motor processes can most 
directly affect mobility, physical safety, and quality of life. By contrast, the “secondary” 
cognitive task is commonly unassessed: there is no measure of the impact of dual-tasking 
on baseline (single-task) cognitive capacity (e.g., accuracy on the cognitive task). Failing 
to assess cognition results in only a partial description of the effects of dual-tasking, 
masking the potential cognitive burden that it imposes. In light of the cognitive 
vulnerabilities associated with PD, it may be as likely that cognition will suffer from 
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cognitive-motor dual-tasking as it is that motor function will suffer. The loss of motor 
automaticity in PD (Hausdorff, Cudkowicz, Firtion, Wei, & Goldberger, 1998; Obeso et 
al., 2000) requires recruitment of attentional and cognitive resources for managing basic 
motor function (motor single-task) (Morris, Iansek, Matyas, & Summers, 1996), thereby 
disadvantaging an already compromised cognitive system; accordingly, dual-task cost to 
at least some aspects of cognition is likely to be substantial. Nonetheless, a 
disproportionately larger emphasis is placed on the motor aspects of gait dysfunction, 
with relatively minimal focus on how cognitive deficits exacerbate problems with gait. 
There is limited, mixed evidence regarding the relation of cognitive performance 
in PD while walking. Rochester and colleagues (Rochester et al., 2014) found no effect of 
dual tasking on digit span performance (short-term memory). Spildooren and colleagues 
(Spildooren et al., 2010) reported more errors in PD with freezing of gait than in PD 
without freezing or in control participants on an auditory association task while turning. 
Yogev and colleagues (Yogev et al., 2005) found more dual-tasking errors in PD than in 
a healthy control group on a Serial 7’s task (counting backward by 7; working memory). 
Executive function remains mainly unexamined although, as described above, it is often 
affected in PD including at the early disease stages. Deficits in set-shifting may be 
particularly vulnerable to the effects of locomotion, since locomotion independently 
requires coordination of multiple motor and cognitive functions.  
The objective of the current study was to investigate the impact of walking on 
cognition, in particular on set-shifting. The hypothesis was that, relative to single-task 
cognitive performance, set-shifting under dual-task conditions would be 
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disproportionately degraded in PD relative to what would be seen in healthy age- and 
education- matched normal control adults (NC). Effects of dual-tasking on cognition 
were first assessed by the interaction between group and task condition (single versus 
dual task) in regard to the mean output across three trials, with the expectation that dual 
tasking would result in a steeper cost to cognition for the PD group than the NC group. 
Next, variability across the three single-task and dual-task trials was assessed, as intra-
individual variability provides an index of cognitive dysfunction (Kalin et al., 2014; 
MacDonald, Li, & Bäckman, 2009; Sliwinski & Buschke, 2004). We expected that 
compared to NC, PD would show a greater increase in cognitive variability on dual task, 
reflecting instability in cognitive output while dual tasking. Finally, direct comparisons 
between PD cognitive and motor function were conducted, with the expectation that dual 
tasking would lead to poorer cognitive output and greater cognitive variability compared 
to motor function.  
 
Hypotheses 
Hypothesis 1: Dual tasking would result in a steeper decline in cognition for PD 
compared to NC as indicated by the interaction between group and task condition (single 
versus dual task).  
Hypothesis 2: Since intraindividual variability offers an index of cognitive 
dysfunction (MacDonald et al., 2009; Sliwinski & Buschke, 2004), variability across the 
three single task and dual task trials were assessed. We expected that compared to NC, 
PD would show a greater increase in cognitive variability on dual task, reflecting 
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instability in cognitive output while dual tasking.  
Hypothesis 3: Dual tasking would relate to poorer cognitive output and greater 
cognitive variability compared to motor function, as assessed by direct comparisons 
between PD cognitive and motor function.  
 
Method 
Participants 
 
Participants included 19 individuals with idiopathic PD (8 women, 11 men) and 
13 NC (8 women, 5 men) (Table 1). All procedures were approved by the Institutional 
Review Board, and consent was obtained according to the Declaration of Helsinki.  
Participants with PD were recruited through the Parkinson’s Disease Clinic at 
Boston Medical Center and other community resources including Fox Trial Finder and 
PD support groups. NC participants were recruited from the general community. 
Exclusion criteria for both groups included reported coexisting serious chronic illness 
(including psychiatric or neurological); history of intracranial surgery, traumatic brain 
injury, alcoholism or other drug abuse; and visual acuity poorer than 20/40 binocular 
(Snellen eye chart; administered in the lab). Use of any psychoactive medication was an 
exclusion criterion for the NC group. The PD group was not taking psychoactive 
medications except for antidepressants and anxiolytics, which are commonly prescribed 
in this disorder. No participant had a clinical diagnosis of Mild Cognitive Impairment or 
dementia, and each obtained a score of 26 or better on the Mini-Mental State 
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Examination (Stern, Sano, Paulson, & Mayeux, 1987), MMSE scoring. 
Diagnosis of idiopathic PD was made by the participants’ neurologists, using UK 
Parkinson’s Disease Society Brain Bank clinical diagnostic criteria (Hughes, Daniel, 
Kilford, & Lees, 1992). They met clinical criteria for mild to moderate disease, with a 
modified Hoehn and Yahr (H&Y) stage range of 1-3 (Hoehn & Yahr, 1967). The PD 
sample included one in stage 1, two in stage 1.5, ten in stage 2, three in stage 2.5, and 
three in stage 3. Disease severity was assessed with the Unified Parkinson’s Disease 
Rating Scale (UPDRS) (Fahn & Elton, 1987; Levy et al., 2005). The mean UPDRS total 
score was 34.8 (SD = 14.5), with a mean motor score of 20.6 (SD = 10.1). Average 
disease duration was 4.9 years (SD = 4.2). Levodopa equivalent dosages (LED), available 
for all participants with PD, were calculated according to Tomlinson and colleagues’ 
conversion formulae (Tomlinson et al., 2010). All were tested in the “on” medication 
state.  
In both groups, psychomotor speed was assessed with the Purdue Pegboard 
(Tiffin, 1948), using the average number of pegs placed bilaterally. To assess mood, we 
used the Beck Anxiety Inventory (Beck & Steer, 1990), Beck Depression Inventory-II 
(Beck, Steer, & Brown, 1996), and the Geriatric Depression Scale (Yesavage et al., 
1982). In the PD group only, subjective quality of life was measured with the 39-item 
Parkinson’s Disease Questionnaire (Peto, Jenkinson, Fitzpatrick, & Greenhall, 1995), and 
the PDQ-39 summary index was calculated (Peto, Jenkinson, & Fitzpatrick, 1998).  
We compared PD and NC on characteristics that may have affected performance 
in this study. There were no significant differences for age, education, ratio of men to 
23 
 
women, or depression. The PD group was slower than NC on the Purdue Pegboard Test, 
as expected. PD participants endorsed significantly more anxiety than NC, but BAI total 
score did not relate to the main cognitive and walking variables, and was not considered 
further in the analyses. 
 
Procedures 
Participants walked over ground at their preferred speed along a constructed 
hallway that was 3.7 m wide, 2.6 m high, and 10.4 m long. The walking surface was a 
dark carpet with white stripes (5cm x 250cm) that were spaced 45cm apart (in use for a 
parallel study). Black curtains were placed on each side along the length of the carpet, 
and the hallway was well lit. Multiple aspects of gait were evaluated using an 
OptoTrack/3020 System (Northern Digital Inc., Waterloo, ON, Canada), with a spatial 
resolution of 0.1 mm. An OptoTrak bank (i.e., position sensor) was placed on each side 
of the walkway and a third OptoTrak bank was located at the front end of the walkway in 
order to capture a full three-dimensional range of movement for at least eight strides. 
Infrared light-emitting diodes (IREDs) were fixed on the participants’ chin and bilaterally 
on the ankle (lateral malleolus), knee (patella), wrist (radiocarpal joint), shoulder 
(humeral head), cheek (2 cm below zygomatic arch), and hip (anterior superior iliac 
spine). Real time position of each IRED was sampled at a rate of 100 Hz and stored to 
disk for further analysis via MatLab (The MathWorks, Inc., Natick, MA). The position 
time-series were filtered using a zero-lag, fourth order, Butterworth, low-pass filter with a 
cut-off frequency of 5 Hz. To account for the increase and decrease in acceleration during 
the speed-up and slow-down phase of each trial, only the middle strides of each trial were 
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included in the analysis. The number of consecutive strides used for analysis ranged from 
four to six. 
After application of the IREDs, participants performed a set of practice trials to 
orient themselves to the walking environment. They were then instructed to walk at their 
preferred speed and to proceed down the middle of the carpeted 10-meter walkway three 
times (single task motor condition). Three baseline walking trials were conducted. 
Dual tasking consisted of walking while performing the Oral Trail Making Test – 
Part B (TMT-B) (Ricker, Axelrod, & Houtler, 1996). This task requires putting numbers 
and letters in alternating increasing sequence. Participants began the task by saying aloud 
“3-C” and continued verbal set-shifting aloud (4-D, 5-E, etc.), starting after the examiner 
said “Ready, Go” and ending once the participant reached the end of the walkway.  
Participants were instructed to perform three trials of TMT-B while walking 
(dual-task condition). To limit practice effects, a distractor task (walking and Serial 7’s – 
counting backward from 100 by 7s) was performed between each dual task trial of 
walking and TMT-B. The single-task cognitive condition (TMT-B) was administered in a 
separate session that occurred an average of 16 days (range: 0-49 days) after the single-
task walking, and dual-task assessment. Because the length of time between tests did not 
differ between groups (t(30) = .68, p = .49) or correlate with cognitive performance (all 
r’s < .10, all p’s > .59), it was not considered further in the analysis. To prevent practice 
effects during dual tasking, single-task cognitive measurements were always collected 
after dual tasking.  
Dependent variables of interest included those for cognition, gait (motor), and 
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inter-trial variability (for both cognition and gait). The measure of cognition (executive 
function, TMT-B), was the ratio of total correct set-shifts (e.g., 3-C, 4-D) to time to 
complete the 10-meter walk (seconds). The measures of gait were for walking speed, 
stride length, and stride frequency. Walking speed (meters per second) for the middle 
strides was estimated by the displacement of the chin marker in the anteroposterior axis, 
divided by the total time to complete the middle strides. Stride length was calculated by 
dividing the total anteroposterior displacement of the respective ankle marker by the 
number of middle strides taken. To account for individual variability in leg length, stride 
length was normalized by dividing the stride length by the individual’s leg length 
(centimeters between the hip and ankle markers). Stride frequency (strides per second; 
Hz) was calculated by dividing the time it took to travel the middle stride distance by the 
number of strides taken. 
 In addition to considering the mean performance across trials, we also assessed 
inter-trial variability of cognition and gait. Variability was indexed by the standard 
deviation of performance on the three trials in each condition (single-task walking, dual-
task walking, single-task cognition, dual-task cognition). 
 
Data analysis  
 Analyses were performed with SPSS 20.0 (SPSS, Inc., Chicago, IL). Four mixed 
design analyses of variance (ANOVAs) were used to examine the main effect of group 
(PD, NC), condition (single, dual task), and the group by condition interaction for each 
dependent variable: TMT-B, walking speed, stride length, and stride frequency. These 
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analyses were completed for mean performance and inter-trial variability. Significant 
interaction effects were followed by planned comparisons using independent and 
dependent samples t-tests. Because of the few number of comparisons made and the 
independence of the four dependent variables, we did not correct for multiple 
comparisons. An alpha level of .05 was chosen for all statistical analyses. 
For direct comparison of cognition to motor function, z-scores were calculated 
with respect to the NC group and repeated measures ANOVAs were used to examine the 
main effect of task type (motor, cognition), condition (single, dual task), and the 
interaction between task type and condition. These ANOVAs were conducted for PD 
only. Significant interaction effects were followed by t-tests.  
 
Results 
 We report the results of performance on the cognitive and walking measures 
(mean performance and inter-trial variability) under single-task and dual-task conditions. 
 
Mean performance 
The ANOVA results for each task are displayed in Table 2 and Figure 1. A 
summary of the findings is highlighted below. 
The main effect of group was significant for walking speed and stride length; PD 
walked with slower speed and shorter stride length. There was a trend for PD to make 
fewer shifts on TMT-B than NC. Comparing single task to dual task, there was a 
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significant main effect of condition for TMT-B, walking speed, stride length, and stride 
frequency. For all variables, mean performance was poorer under the dual-task than the 
single-task condition. There was a significant group by condition interaction for walking 
speed and stride frequency; dual tasking affected walking speed and stride frequency in 
PD more than NC.  
Independent samples t-tests showed comparable performance of PD and NC on 
single-task measurement of stride frequency (p = .49) and a trend for slower walking 
speed in PD [t(30) = 1.96, p = .06]. On dual task, PD had lower stride frequency [t(30) = 
2.23, p = .03] and slower walking speed [t(17.47) = 2.54, p = .02] than NC. Paired 
samples t-tests comparing single to dual tasking showed a significant effect for PD and 
NC on walking speed [PD: t(18) = 10.50, p < .001; NC: t(12) = 10.13, p < .001]. A 
significant effect of dual tasking was found for stride frequency for PD [t(18) = 7.46, p < 
.001], with a trend for NC [t(12) = 1.85, p = .09].  
The group by condition interaction was not significant for TMT-B, however, 
planned comparisons were still conducted between PD and NC on single and dual task 
TMT-B performance. PD had fewer TMT-B shifts on dual tasking [t(30) = 2.07, p = 
.047], but not on single tasking (p = .13). Paired samples t-tests showed an effect of dual 
tasking for both PD and NC [PD: t(18) = 5.64, p < .001; NC: t(12) = 8.03, p < .001]. 
 
Inter-trial Variability 
 
For all variables, there was no main effect of group (all p’s >.12) or of condition 
(all p’s >.43). The interaction effect was not significant for walking speed, stride length, 
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or stride frequency (all p’s > .85). There was a trend for a group by condition interaction 
for TMT-B shifts, [F(1, 30) = 4.11, p = .052]. PD showed no difference in inter-trial 
variability from single to dual task (p = .38), whereas NC showed a reduction in inter-
trial variability on dual task [t(12) = 2.23, p = .045]. On dual task, inter-trial variability 
was greater for PD than NC [t(26.67) = 2.69, p = .01]; inter-trial variability on single task 
was comparable between PD and NC (p = .79). 
 
Cognition-Motor Comparison 
The following analyses used z-scores with respect to NC in order to allow for 
direct comparison of cognitive and motor function.  
Mean Performance: PD task type by condition interaction 
When considering PD function with respect to NC, there was a significant effect 
of condition for stride frequency [F(1,18) = 8.72, p = .009, ŋ2 = .33], with a trend for 
walking speed [F(1,18) = 4.02, p = .06, ŋ2 =  .18]. This is consistent with the above 
results that indicated a greater impact of dual tasking on stride frequency and walking 
speed for PD than NC. The effect of condition was not significant for stride length (p = 
.18). When directly comparing task type (cognitive versus motor function), the main 
effect was not significant (all p’s > .34). The task type by condition interaction was not 
significant for any variable (all p’s > .18). 
Inter-trial Variability: PD task type by condition interaction 
There was a main effect of task type, with cognitive variability exceeding the 
variability of walking speed, stride length, and stride frequency. The main effect of 
29 
 
condition was significant for all variables, with dual tasking resulting in greater 
variability compared to single tasking. There was a task type by condition interaction 
effect for stride length and stride frequency, and a trend for walking speed. Cognitive 
variability was greater under dual task than under single task conditions [t(18) = -3.19, p 
= .005], whereas motor variability remained constant across conditions (all p’s > .64). 
Though cognitive and motor variability were comparable for the single task condition (all 
p’s > .54), cognitive variability was greater than motor variability for the dual task 
condition – walking speed [t(18) = 2.17, p = .04], stride length [t(18) = 3.33, p = .004], 
stride frequency [t(18) = 2.65, p = .02]. Results are displayed in Table 3 and Figure 2. 
 
Discussion 
This study assessed the impact of dual tasking on cognition in PD with the 
hypothesis that dual tasking would not only affect motor function, but would also affect 
cognition. This hypothesis arises from the characterization of PD as a disease marked by 
diminished motor automaticity, in which cognitive resources are required to facilitate the 
production of movements that are typically automatic and effortless. In a sense, PD 
locomotion is in itself a dual task in that it requires cognitive control while 
simultaneously engaging in the motor demands of locomotion. Consequently, the 
addition of attentional or cognitive demands should result in notable compromises in 
performance of a dual cognitive-motor task.  
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Cognition 
We found that individuals with PD demonstrated an overall tendency to produce 
fewer set shifts than did NC. Dual tasking impacted the mean output of set shifts for both 
PD and NC similarly. Although the group by condition interaction was not significant, 
PD had fewer set-shifts than NC on dual task. Dual tasking had a greater impact on 
cognitive inter-trial variability for PD than NC, as reflected by the trend for a group by 
condition interaction. For PD, the impact of dual tasking on cognitive variability was 
significantly greater than the impact of dual tasking on motor variability.  
These results support the long-documented evidence of reduced set-shifting 
capacity in PD (e.g., Cronin-Golomb et al., 1994), and demonstrate that cognition is 
impacted by dual tasking. Particularly, PD cognition was characterized by variability in 
cognitive output under dual tasking. Though overall cognitive output was not strikingly 
different than NC, the greater variability in PD may represent a marker of dysfunction in 
dual cognitive-motor processes. The NC group showed less variability in cognitive output 
on dual tasking than the PD group, suggesting that PD affects the ability to sustain 
cognitive output as task demands increase. Further, the pattern of PD cognitive 
dysfunction contrasted with the pattern of PD motor dysfunction. Although PD motor 
output showed an overall reduction on dual tasking relative to single tasking, variability 
in motor performance remained unaffected by dual tasking, whereas cognitive 
performance in PD was marked by significantly greater variability under dual tasking. Of 
note, these effects occurred for individuals with mild to moderate PD, and were observed 
while walking a very short distance, under highly controlled conditions. Even under these 
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conditions that were not particularly challenging, the participants with PD showed 
cognitive vulnerabilities, suggesting that deleterious effects on cognition may be more 
prevalent in everyday environments that are less predictable and that feature greater 
environmental demands.  
 
Gait 
Individuals with PD walked with shorter strides and slower speed than NC. In 
both the PD and NC groups, dual tasking resulted in a decline in walking speed, stride 
length, and stride frequency, relative to the single-task walking condition. Compared to 
NC, dual tasking resulted in particular decrements in PD walking speed and stride 
frequency. The significant group by condition interaction indicates particular 
vulnerabilities in walking speed and stride frequency under dual tasking in PD, which is 
consistent with the traditional motor symptoms of this disorder.  
These findings highlight the impact of PD on aspects of walking, and point to 
practical implications. As we and others have found, walking dysfunction in PD consists 
of classic motor symptoms (e.g., reduced walking speed) that may be particularly 
exacerbated when combined with cognitive vulnerabilities (Yogev-Seligmann, 
Hausdorff, & Giladi, 2008). In this study, this was most clearly seen in the effect of dual 
tasking on stride frequency. Even though stride frequency problems are a common 
consequence of PD (Morris, Iansek, McGinley, Matyas, & Huxham, 2005; Young et al., 
2010), in this study, PD stride frequency was comparable to that of NC under single task 
conditions. Under the demands of dual tasking relative to single tasking, PD stride 
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frequency significantly declined, and this decline was greater than that seen in NC. Until 
faced with combined cognitive and motor demands, PD function resembled that of NC, 
highlighting the PD disadvantage in locomotion under attentional demands. Since PD is 
associated with limited capacity to allocate cognitive resources (Bloem, Grimbergen, van 
Dijk, & Munneke, 2006; Dubois & Pillon, 1997), it is unsurprising that dual-tasking 
deficits were observed in PD.  
 
Neural substrates of dual task effects 
Considering the complex demands of navigating the environment, including 
planning, visual processing, goal-directed execution of behavior, and coordination of 
limbs, a better understanding of key neural structures and circuits responsible for these 
results may offer important insight into potential treatment targets. Most imaging 
research on gait dysfunction in PD has been limited to investigations of freezing of gait 
(Shine et al., 2013; Tessitore, Amboni, et al., 2012). In light of the cognitive and motor 
vulnerabilities described in the present study, specific consideration should be placed on 
the relation of walking dysfunction to reduced functional connectivity of core attentional-
cognitive networks. Rowe and colleagues found an absence of effective connectivity 
between the prefrontal cortex (PFC) and the lateral premotor cortex and the 
supplementary motor area in PD (Rowe et al., 2002). More recent research has 
highlighted the role of disrupted connectivity between the default mode network (DMN) 
and networks important for attention and executive function (Shine et al., 2013). PD 
shows abnormal activation of the PFC and DMN, suggesting disruption of these frontal-
basal ganglia circuits (Tinaz, Schendan, & Stern, 2008). Putcha and colleagues (Putcha et 
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al., 2015) noted abnormal resting state connectivity between the DMN and the central 
executive network (CEN) in PD. Whereas DMN and CEN interactions are typically anti-
correlated in healthy individuals, those with PD showed greater DMN-CEN coupling at 
rest. Further, decreased connectivity in the DMN relates to severity of cognitive 
dysfunction in PD (Tessitore, Esposito, et al., 2012). Van Eimeren and colleagues (van 
Eimeren, Monchi, Ballanger, & Strafella, 2009) reported the disturbance of the DMN 
during a card sorting task, speaking to the relation between DMN abnormalities in PD 
and executive function. Gait vulnerabilities may further be exacerbated by disrupted 
connections between the DMN and attentional networks that compromise the ability to 
accurately perceive aspects of the environment or to develop an appropriate response 
(Shine et al., 2011).  
Taken together, these studies describe specific deficits to cognitive networks 
responsible for attention and executive function. As noted above, the investigation of 
neural networks related to gait has mainly been limited to freezing of gait. The results of 
the present study raise the expectation of a relation between disrupted functional 
connectivity of cognitive networks and the presence of both cognitive and motor deficits 
associated with dual tasking in PD, a prediction that will need to be assessed through 
future research.  
 
Limitations 
This study was subject to several limitations beyond the sample size. We 
examined only mild to moderate PD, and cannot generalize our results to individuals with 
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more severe disease. Because those with more severe motor dysfunction are often also 
those with more advanced cognitive dysfunction, we would expect the interaction 
between motor and cognitive impairments to be even greater with increased disease 
severity. Another limitation was that this research was conducted in a research lab and 
the participants were confined to a walkway while wearing IREDs to collect kinematic 
data. Having now provided baseline information under controlled conditions, we suggest 
that future studies may enhance the ecological validity of these results, and presumably 
reveal even stronger PD effects, by use of a relatively unconfined space and simulation of 
more typical environmental demands (e.g., walking around moving and stationary 
obstacles, distraction by sounds, changing physical settings). A further potential 
limitation was that single- and dual-task cognitive data were collected on separate days 
(dual-task first) in order to minimize practice effects during dual tasking (which was the 
primary focus of the study) and to limit fatigue. It should be noted, however, that the 
mean time between single-and dual-task cognitive assessment was the same for PD and 
NC, and did not relate to cognitive performance, suggesting that the task order was not 
consequential. 
 
Conclusions 
The combined effect of dual tasking on cognition and gait reflects limitations in 
the ability of individuals with PD to manage the complex cognitive and motor demands 
of locomotion. Targeting walking dysfunction in PD has been shown to improve gait 
speed (Uc et al., 2014), balance and self-reported activities of daily living (Tomlinson et 
al., 2012), reduce the risk of falls (Morris et al., 2015), and enhance health-related quality 
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of life (Tickle-Degnen, Ellis, Saint-Hilaire, Thomas, & Wagenaar, 2010). Though 
physical interventions aimed at improving walking promote this goal, such treatments 
may be incomplete without considering simultaneous interventions to maximize 
cognition. A combination of cognitive interventions and physical rehabilitation may 
prove to be the most effective approach to optimize walking, while also promoting the 
individual’s ability to engage in cognition during locomotion, the need for which occurs 
commonly in everyday life. Future research may offer important contributions by 
determining the cognitive functions most compromised during dual tasking in PD and 
developing compensatory interventions that benefit both cognition and gait.  
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Tables and Figures 
Table 1  
Participant Characteristics 
______________________________________________________________________________ 
 
 
PD (n=19) 
___________ 
 
NC (n=13) 
___________ 
 
Significance 
___________ 
 
Age (years) 66.3 (5.6) 63.2 (4.5) NS 
Education (years) 17.4 (1.8) 17.3 (2.4) NS 
Women:Men 8:11 8:5 p=.28 
Beck Anxiety Inventory 5.5 (5.0) 0.9 (1.6) p<.01 
Beck Depression Inventory-II 5.1 (4.0) 2.6 (4.4) NS 
Geriatric Depression Scale 3.4 (3.3) 2.3 (2.9) NS 
Purdue Pegboard (left hand) 11.2 (2.4) 14.1 (1.9) p<.01 
Purdue Pegboard (right hand)  11.9 (2.2) 14.6 (1.6) p<.01 
UPDRS Total 34.8 (14.5) - - 
UPDRS Motor Score 20.6 (10.1) - - 
PD Duration (years) 4.9 (4.2) - - 
H&Y (median, range) 2 (1-3) - - 
LED (mg/day) 161.9 (141.1) - - 
PDQ-39 Summary Index 18.2 (18.8) - - 
______________________________________________________________________________ 
PD = Parkinson's disease; NC = Normal control participants. UPDRS = Unified 
Parkinson's Disease Rating Scale; H&Y = Hoehn & Yahr stage; LED = Levodopa 
equivalent dose; PDQ-39 = 39-item Parkinson’s Disease Questionnaire; Values presented 
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are means (standard deviations), unless otherwise indicated. The last six measures were 
specific to PD. 
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Table 2 
ANOVA Results for PD and NC under Single-Task and Dual-Task Conditions for 
Cognition (TMT-B) and Walking (Speed, Stride Length, Stride Frequency) 
TMT-B  Mean (SE) F-value (df) 
eta-
squared p-value 
Group 
PD .54 (.02) 
3.91 (1, 30) .12 .06 NC .61 (.03) 
Condition 
Single Task .63 (.02) 
60.95 (1, 30) .67 < .001 Dual Task .51 (.02) 
Group x 
Conditon 
 
PD Single Task .60 (.03) 
.75 (1, 30) .02 .39 
 
PD Dual Task .47 (.03) 
 
NC Single Task .67 (.03) 
 
NC Dual Task .56 (.03) 
Walking Speed  Mean (SE) F-value (df) 
eta-
squared p-value 
Group 
 
PD 1.07 (.04) 5.90 (1, 30) .16 .02  
NC 1.24 (.05) 
Condition  
 
Single Task 1.24 (.03) 172.92 (1, 30) .85 < .001  
Dual Task 1.07 (.04) 
Group x 
Conditon 
 
PD Single Task 1.18 (.04) 
5.84 (1, 30) .16 .02 
 
PD Dual Task .97 (.05) 
 
NC Single Task 1.31 (.05) 
 
NC Dual Task 1.17 (.05) 
Stride Length  Mean (SE) F-value (df) 
eta-
squared p-value 
Group 
 
PD 1.50 (.05) 5.06 (1, 30) .14 .03  
NC 1.68 (.06) 
Condition  
 
Single Task 1.65 (.04) 80.86 (1, 30) .73 < .001  
Dual Task 1.53 (.04) 
Group x 
Conditon 
 
PD Single Task 1.56 (.05) 
1.59 (1, 30) .05 .22 
 
PD Dual Task 1.43 (.06) 
 
NC Single Task 1.73 (.06) 
 
NC Dual Task 1.63 (.07) 
Stride Frequency  Mean (SE) F-value (df) 
eta-
squared p-value 
Group 
 
PD .86 (.02) 2.64 (1, 30) .08 .12  
NC .89 (.02) 
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Condition  
 
Single Task .91 (.01) 34.43 (1, 30) .53 < .001  
Dual Task .85 (.02) 
Group x 
Conditon 
 
PD Single Task .89 (.02) 
6.79 (1, 30) .18 .01 
 
PD Dual Task .82 (.02) 
 
NC Single Task .91 (.02) 
 
NC Dual Task .88 (.02) 
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Table 3 
ANOVA Results for PD Inter-trial Variability. Z-scores for Cognition (TMT-B) and 
Walking (Speed, Stride Length, Stride Frequency) in PD 
Walking Speed  Mean (SE) F-value (df) eta-squared p-value 
Task Type 
 
TMT-B 
 
.84 (.36) 3.28 (1, 18) .15 .09  
Walking Speed 
 
.26 (.20) 
Condition  
 
Single Task 
 
.15 (.18) 10.95 (1, 18) .38 .004  
Dual Task 
 
.95 (.34) 
Task x Conditon 
 
TMT-B 
Single Task 
 
.11 (.31) 
4.03 (1, 18) .18 .06 
 
TMT-B 
Dual Task 
 
1.56 (.51) 
 
Walking Speed 
Single Task 
 
.18 (.12) 
 
Walking Speed 
Dual Task 
 
.34 (.35) 
Stride Length  Mean (SE) F-value (df) eta-squared p-value 
Task Type 
 
TMT-B 
 
.84 (.36) 7.20 (1, 18) .29 .02  
Stride Length 
 
-.09 (.12) 
Condition  
 
Single Task 
 
.02 (.20) 7.22 (1, 18) .29 .02  
Dual Task 
 
.74 (.28) 
Task x Conditon 
 
TMT-B          
Single Task 
 
.11 (.31) 
10.20 (1, 18) .36 .005 
 
TMT-B             
Dual Task 
 
1.56 (.51) 
 
Stride Length 
Single Task 
 
-.08 (.17) 
 
Stride Length   
Dual Task 
 
-.09 (.14) 
Stride 
Frequency  Mean (SE) F-value (df) 
eta-
squared p-value 
Task Type 
 
TMT-B 
 
.84 (.36) 4.42 (1, 18) .20 .05  
Stride Frequency 
 
.14 (.11) 
Condition  
 
Single Task 
 
.11 (.20) 10.40 (1, 18) .37 .005  
Dual Task 
 
.87 (.27) 
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Task x Conditon 
TMT-B          
Single Task 
 
.11 (.31) 
5.78 (1, 18) .24 .03 
 
TMT-B             
Dual Task 
 
1.56 (.51) 
 
Stride Frequency 
Single Task 
 
.10 (.20) 
Task x Conditon Stride Frequency Dual Task .18 (.14) 10.20 (1, 18) .36 .005 
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Figure 1 
 
Comparisons of PD and NC performance on measures of cognition and walking under 
single- and dual-task conditions. There was a significant main effect of condition on 
cognition (Trail Making Test-B, TMT-B) and walking (speed, stride frequency, and stride 
length), with worse performance under the dual- than the single-task condition. There 
was a significant main effect of group for walking speed and stride length, and a trend for 
cognition. The interaction was significant for walking speed and stride frequency. 
Compared to NC, PD had slower walking speed, lower stride frequency, and fewer TMT-
B set shifts on dual task, despite comparable performance on single task.  
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Figure 2 
 
Inter-trial variability for PD group on cognition and walking variables. Z-scores represent 
PD performance relative to NC. Effect of condition: For cognition (Trail-Making Test-B, 
TMT-B) but not for walking (speed, stride length, stride frequency), there was a 
significant difference in inter-trial variability between the single- and dual-task conditions 
(dual-task performance worse). Effect of task type: For the dual-task condition, inter-trial 
variability was significantly greater for cognition than for walking (speed, stride length, 
and stride frequency). For the single-task condition, there were no significant differences 
in inter-trial variability between cognition and any walking variable.  
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CHAPTER 3:  STUDY TWO | SPATIAL BIAS IN PARKINSON’S DISEASE: 
CONTRIBUTIONS OF ATTENTIONAL AND EXECUTIVE DYSFUNCTION 
© American Psychological Association, 2019. This paper is not the copy of record and 
may not exactly replicate the authoritative document published in the APA journal. 
Please do not copy or cite without author's permission. The final article is available, upon 
publication, at: https://doi.org/10.1037/bne0000329  
 
Introduction 
Parkinson’s disease is characterized by dopaminergic deficits in the substantia 
nigra that result in disruptions to cortical-striatal circuitry. Hallmark motor symptoms of 
PD include tremor, rigidity, bradykinesia, and disturbances of gait, balance, and posture, 
accompanied by a host of non-motor symptoms that have a significant impact on quality 
of life. Among the common non-motor symptoms experienced by individuals with PD 
are changes in vision (Amick, Cronin-Golomb, & Gilmore, 2003; Archibald, Clarke, 
Mosimann, & Burn, 2011; Bodis-Wollner, Glazman, & Yerram, 2013; Bodis-Wollner et 
al., 1987; Castelo-Branco et al., 2009; Diederich, Fénelon, Stebbins, & Goetz, 2009; 
Matsui et al., 2006; Pieri, Diederich, Raman, & Goetz, 2000; Seichepine et al., 2011; Uc 
et al., 2005; Urwyler et al., 2014; Weil et al., 2016) and visuospatial function (Clark et 
al., 2008; Davidsdottir et al., 2005; Kemps, Szmalec, Vandierendonck, & Crevits, 2005; 
Possin, Filoteo, Song, & Salmon, 2008; Seichepine et al., 2015), including spatial bias in 
perception and navigation (Davidsdottir et al., 2008; Lin et al., 2014; Ren et al., 2015; 
Young et al., 2010). In neurological populations such as stroke, spatial bias including 
left-side hemineglect may follow from lesions of the right posterior parietal lobe. Line 
bisection studies in PD have documented an asymmetric spatial bias that is similar in 
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kind; individuals with motor onset on the left side of the body (LPD; predominant 
damage to right basal ganglia) have been reported to bisect more to the right than those 
with right-side onset PD (RPD; left hemispheric deficits) and healthy adults (Lee et al., 
2001). Relative to stroke, in PD the extent of bias is milder. Spatial bias in PD does not 
appear to be accounted for by hemifield deficits in basic vision or perception, such as 
spatial compression, reduced salience, or retinal structure (Laudate et al., 2013; Norton, 
Jaywant, Gallart-Palau, & Cronin-Golomb, 2015). By contrast, eye movement patterns 
during line bisection suggest that attentional effects may contribute to spatial bias 
(Laudate et al., 2013). There has been little further examination of this possibility. 
Disruptions of attention and executive function occur commonly in PD, even 
early in the disease course (Miller et al., 2013), reflecting compromise of fronto-parietal 
systems (Amick, Schendan, Ganis, & Cronin-Golomb, 2006; Baggio et al., 2015; 
Madhyastha et al., 2015; Schendan et al., 2009; Tinaz et al., 2008). Asymmetries of 
visual attention and processing have been documented, with LPD requiring more search 
time for objects in the left visual hemifield and RPD requiring more search time in the 
right hemifield (DeGutis et al., 2016). This directional asymmetry does not occur in all 
individuals with the disorder, however (Davidsdottir et al., 2008; Nys, Santens, & 
Vingerhoets, 2010; Ren et al., 2015). As attention and executive function are often 
affected in PD, it is conceivable that changes in these processes may underlie the 
development of spatial bias. 
In order to address this possibility, we made use of a line-bisection paradigm 
using directional cuing to engage attention in the right vs. left sides of visual space. To 
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date, most research on spatial bias in PD has used static stimuli, though spatial judgments 
are rarely made in static space and are dependent upon constant monitoring and updating 
of spatial information. Here we manipulated the visual field in which spatial judgments 
were made in order to assess whether directing attention to the left or right would affect 
spatial judgment. Since the dominant hemispheric pathology of LPD and RPD is by 
definition different (LPD having more dysfunction of the right hemisphere, RPD more 
dysfunction of the left hemisphere), an LPD-RPD difference would provide insight into 
the brain structures affecting spatial bias in PD. Specifically, if there were a type of 
parietal-based neglect, we would not see significant bias on line bisection in RPD or NC, 
but would see it in LPD. In this subgroup, when the target is presented in the left visual 
field (LVF), there would be spatial bias to the right of center, and when the target is 
presented in the right visual field (RVF), there would be relatively strong bias to the 
right, both results consistent with right parietal dysfunction. If there were no effect of side 
of motor symptom onset and visual field, the interpretation in regard to neuropathological 
processes would be that spatial judgment is less directed by lateralized brain regions, and 
more affected by the (bilateral) frontal-subcortical pathology commonly seen in PD. In 
the latter case, there should be a correlation between spatial judgment and performance 
on neuropsychological assessments of executive function.  
Two hypotheses were contrasted – a frontal-executive hypothesis and a parietal-
neglect hypothesis.  
Hypothesis 1: If spatial judgment in PD is primarily driven by a parietal-neglect 
syndrome, those with LPD, but not those with RPD, would show a rightward spatial bias, 
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consistent with right parietal dysfunction. For LPD, initial placement of the stimulus in 
the RVF would result in rightward spatial bias (i.e., enhancing neglect of the left 
hemifield), relative to results with RPD and NC, whereas initial placement of the 
stimulus in the LVF would result in more similar performance across the three groups, 
with the possibility of some relative rightward bias by the LPD subgroup. Spatial 
judgment would be independent of performance on neuropsychological assessments of 
frontal-executive function.  
Hypothesis 2: If spatial judgment in PD is primarily driven by frontal-executive 
deficits, perceived center would occur independently of side of motor symptom and 
visual field. Instead, perceived center would be shifted in the direction of the attentional 
manipulation (whether right or left), and the degree of spatial bias would be correlated 
with impairments on neuropsychological assessments of attention and executive function. 
Because frontal-type impairments occur regardless of side of PD onset, the correlations 
should be similar in LPD and RPD.  
In addition to considering a parietal-driven versus a frontal-driven hypothesis in 
regard to spatial judgment in PD, we acknowledge that these brain systems are often 
interactive, and hence the hypotheses are not mutually exclusive. That is, the “frontal” 
component of fronto-parietal pathology may lead to spatial bias in all individuals with 
PD, in both visual fields (in accordance with the direction in which attention is directed), 
while the “parietal” component of the pathology may simultaneously lead to a tendency 
toward rightward bias specific to LPD. In this case we would expect to see the parietal 
pattern of results for LPD (differing from the other groups in rightward bias especially in 
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RVF) plus we would see an effect of visual field of presentation for RPD (leftward bias 
in LVF, rightward bias in RVF), as well as a correlation of bias with performance on the 
executive/attentional tests. 
 
Method 
Participants 
Participants included 79 with idiopathic PD (35 women, 44 men) and 67 age- and 
education- matched normal control adults (NC) (47 women, 20 men) (Table 4). All 
procedures were approved by the Boston University Charles River Campus Institutional 
Review Board, and consent was obtained according to the Declaration of Helsinki.  
Individuals with PD were recruited through the Parkinson’s Disease Clinic at 
Boston Medical Center and other community resources including Fox Trial Finder and 
PD support groups. NC participants were recruited from the general community. 
Exclusion criteria for both groups included reported coexisting serious chronic illness 
(including psychiatric or neurological); history of intracranial surgery, traumatic brain 
injury, alcoholism or other drug abuse; visual acuity poorer than 20/40 binocular (Snellen 
eye chart; administered in the lab); use of psychoactive medications besides 
antidepressants and anxiolytics in the PD group, which are commonly prescribed; use of 
any psychoactive medication in the NC group. PD and NC participants were not 
demented as indicated by scores on the modified form of the Mini-Mental State 
Examination (Stern et al., 1987), each obtaining 26.25 or better on conversion to standard 
MMSE scoring.  
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Diagnosis of idiopathic PD was made by the participants’ neurologists, using 
United Kingdom Parkinson’s Disease Society Brain Bank clinical diagnostic criteria 
(Hughes et al., 1992). Participants met clinical criteria for mild to moderate disease, with 
a Hoehn and Yahr stage range of 1-3 (Goetz et al., 2004). The PD sample included 10 in 
stage 1, 16 in stage 1.5, 28 in stage 2, 14 in stage 2.5, and 11 in stage 3. Disease severity 
was assessed with the Unified Parkinson’s Disease Rating Scale (Fahn & Elton, 1987; 
Levy et al., 2005). The mean UPDRS total score was 36.6 (SD = 14.9), with a mean 
motor score of 21.0 (SD = 9.8). Average disease duration was 6.4 years (SD = 4.4). 
Levodopa equivalent dosages (LED), available for all participants with PD, were 
calculated according to Tomlinson and colleagues’ conversion formulae (Tomlinson et 
al., 2010). All participants were tested in the “on” medication state.  
In both groups, psychomotor speed was assessed with the Purdue Pegboard 
(Tiffin, 1948), using the average number of pegs placed with the left and right hands. To 
assess mood, we used the Beck Anxiety Inventory (Beck & Steer, 1990), Beck 
Depression Inventory-II (Beck et al., 1996), and the Geriatric Depression Scale 
(Yesavage et al., 1982). In the PD group only, subjective quality of life was measured 
with the 39-item Parkinson’s Disease Questionnaire (Peto et al., 1995). 
We compared PD and NC on characteristics that may have affected performance 
in this study (Table 4). There were no significant differences in age, education, or ratio of 
men to women. The PD group was slower than NC on the Purdue Pegboard Test and 
endorsed more anxiety and depression, which are expected consequences of PD. Anxiety 
and depression did not correlate with the main variables, and were not considered further 
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in the analysis. The LPD and RPD subgroups were matched on all variables except 
Purdue Pegboard, for which those with RPD performed more poorly than LPD with the 
left hand (p<.04).  
 
Procedures 
Line Bisection  
A dynamic Landmark-like test was administered, using the method of adjustment. 
The stimulus was presented binocularly to participants on an LCD computer screen 
approximately 19.75 in. diagonal, 10.75 in. vertical, and 17 in. horizontal. The stimulus 
was a black horizontal line approximately 13.25 in. in length, bisected by a black vertical 
cursor approximately 2 in. in height, presented in the center of the screen on a white 
background. The vertical cursor was initially presented as offset from the center of the 
horizontal line by 10% of the total length of the horizontal line and moved toward the 
center of the horizontal line. Ten trials were administered and were evenly 
counterbalanced for the side of the line (hemifield) in which the vertical cursor was 
initially displayed. The first trial began with the vertical cursor on the right. The vertical 
cursor began on the left for the next trial and continued to alternate on successive trials 
for a total of ten trials. Across the ten trials, trials that began with the cursor on the left 
are referred to as Landmark (LM)-left and those with the cursor beginning on the right as 
LM-right. To eliminate motor demands on the participant, the experimenter moved the 
cursor across the horizontal line at .5% the total length of the horizontal line per second, 
and the participant indicated when the perceived center had been reached. The trials were 
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untimed and participants could request that the position of the bisector be adjusted in 
either direction until they were satisfied with the position (i.e., method of adjustment).  
For analysis, the bisected line was conceptualized as a number line. The true 
center was represented by zero, and increasingly greater distances from center were 
represented by more positive numbers for rightward deviations and more negative 
numbers for leftward deviations. The score for each trial was mean percent bias from the 
true midline (range: -10 to 10). The values of all responses were averaged for the five 
LM-left trials and the five-LM right trials to produce the LM-total score. In addition to 
assessing the mean of the LM-left and LM-right trials, inter-trial variability was 
considered with the standard deviation of the five LM-left and five LM-right trials. 
 
Cognitive Assessment 
The following neuropsychological tests were used to assess the relation between spatial 
bias and attention/executive function. 
Stroop Color-Word task (Stroop, 1935); executive function: Participants named the colors 
of xxx’s (Stroop Color), read color words (in black ink; Stroop Word), and named the 
color of ink in which incongruent ink/color words were written (Stroop Color-Word), 
each as quickly as possible.  
Trail Making Test (Tombaugh, 2004); attention, set-shifting, and executive function: 
Participants quickly drew lines connecting numbers in order for Condition A (attention). 
For Condition B, participants quickly drew lines alternating between numbers and letters 
in order (set-shifting, executive function).  
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Delis-Kaplan Executive Functioning System (Delis, Kaplan, & Kramer, 2001; Delis, 
Kramer, Kaplan, & Holdnack, 2004) (DKEFS) Verbal Fluency: Participants verbally 
generated words within phonemic categories (F, A, S). Performance for each trial was 
measured by total output across 60 seconds, excluding repeated words and set loss errors.  
Digit Span Wechsler Memory Scale III (Wecshler, 1997); attention (Forward and 
Backward conditions) and working memory(Backward condition). Participants first 
repeated digit sequences in the original order (Forward), and then repeated digit 
sequences in reverse order (Backward). 
Spatial Span Wechsler Memory Scale III  (Wechsler, 1997); spatial attention (Forward 
and Backward conditions) and spatial working memory (Backward condition):  
Participants first repeated block sequences by touching the blocks in the same order in 
which the examiner had done so (Forward), and then touched the blocks in reverse order 
(Backward). 
 
Statistical analysis  
 Analyses were performed with SPSS 20.0 (SPSS, Inc., Chicago, IL). Analyses of 
variance (ANOVAs) were used to examine the effect of group (PD-NC); effect of initial 
side of bisector presentation (hemifield) (LM-left, LM-right), and the interaction of group 
by hemifield. A separate set of ANOVAs assessed the effect of side of onset (LPD, 
RPD); effect of hemifield, and the interaction of side of onset (LPD, RPD) by hemifield. 
Significant interaction effects were followed by independent samples t-tests and paired 
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samples t-tests. Pearson correlations were conducted between LM performance and 
cognitive tests. To assess whether the strength of the correlation between LM 
performance and performance on each of the cognitive tests was different for PD and NC, 
Fisher’s r-to-z transformations were conducted. For all correlations, an alpha of .01 was 
used to correct for multiple correlations.  
 
Results 
Results for the Landmark Line Bisection task are displayed in Table 5 (mean percent 
bias) and Table 6 (standard deviation). Standard deviation was used as a measure of inter-
trial variability. 
 
Main effect of group 
Mean Percent Bias: The main effect of group was significant for LM-total and LM-left, 
with PD bisecting farther left than NC. The main effect of group for LM-right was not 
significant. 
Standard Deviation: The main effect of group was significant for LM-total, LM-left, and 
LM-right. For all, the PD standard deviation was greater than that of NC. 
  
Main effect of hemifield 
Mean Percent Bias: The main effect of hemifield was significant. LM-left trials were 
bisected leftward of right trials.  
Standard Deviation: The main effect of hemifield was not significant. 
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Interaction effect: Group-by-Hemifield 
Mean Percent Bias: The group-by-hemifield interaction effect was significant. 
Independent samples t-tests showed a significant group difference on LM-left trials, with 
PD bisecting farther left than NC [t(144) = -3.40, p < .001]. For LM-right trials, PD and 
NC did not differ [t(144) = -.41, p < .68]. Paired samples t-tests showed a significant 
difference between extent of bias on LM-left and LM-right trials for PD and for NC [PD: 
t(78) = 13.6, p < .001; NC: t(68) = 11.2, p < .001]; that is, the extent of bias to the left on 
LM-left trials was greater than the extent of bias to the right on LM-right trials. 
Standard Deviation: The group-by-hemifield interaction effect was significant. 
Independent samples t-tests showed a significant group difference on LM-left and LM-
right trials, with PD showing a larger standard deviation [LM-left trials: t(144) = 3.7, p < 
.001; LM-right trials: t(141.07) = 4.4, p < .001]. Paired samples t-tests indicated no 
significant difference in standard deviation between LM-left and LM-right trials for 
either PD [t(78) = -.61, p > .54] or NC [t(66) = .09, p > .93]. That is, the PD group 
showed more variability in performance than the NC group, regardless of whether a trial 
began on the right or left of center. 
 
Side of onset: LPD, RPD, NC 
Side of motor symptom onset did not have an effect on spatial judgment, with the 
exception of standard deviation for LM-right, with LPD showing a greater standard 
deviation than RPD (t(77) = -2.01, p < .048). The main effects and interaction effects 
replicated the PD-NC results, and will not be described further (see Table 5).  
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The results of cognitive testing are presented in Table 7. 
 
Correlations 
All correlations between LM performance and cognition are displayed in Table 8. Since 
primary interest is in the strength of the correlation between LM performance and 
cognition, only Fisher’s r-to-z transformations are described below.  
 
Fisher’s r-to-z transformations: PD-NC correlation comparisons [LM bias, cognition]  
 
Mean Percent Bias. For LM-left, the correlation between cognition and extent of spatial 
bias was stronger for PD than NC for spatial span forward, spatial span backward, TMT-
B, and phonemic fluency. For LM-right, there was no significant PD-NC difference in the 
strength of the correlation with any cognitive variable.  
 
Standard Deviation. Because there was no effect of hemifield (that is, side that the trial 
was initiated from) on standard deviation for PD or NC, we used the average standard 
deviation of all 10 LM trials. The correlation between cognition and LM–total standard 
deviation was greater for PD than NC for the following measures: Spatial span forward, 
spatial span backward, Trail Making Test A, Trail Making Test B, Stroop color-word 
reading, and phonemic fluency. 
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Discussion 
We examined spatial judgement in PD on a landmark line bisection task that 
directed attention to one or the other side of space, with the goal of evaluating two 
hypotheses regarding mechanisms of spatial bias in PD: (1) parietal-neglect, and (2) 
frontal-executive. To do so, we compared the performance of PD subgroups. Support for 
the parietal-neglect hypothesis would have been provided had the subgroup with LPD 
(predominant right-hemisphere dysfunction) shown more rightward bias than the 
subgroup with RPD (predominant left-hemisphere dysfunction). Our results did not 
support this hypothesis, as there was no LPD-RPD difference in perceived center, 
regardless of the side on which the bisector first appeared. The absence of LPD-RPD 
differences suggests that dynamic spatial judgment on this type of task does not depend 
on lateralized cortical-subcortical function. 
The pattern of results instead better aligned with the frontal-executive hypothesis. 
Relative to NC, those with PD had significantly greater variability in performance (larger 
standard deviation) than the NC group, meaning that for PD, their perceived “center” 
shifted across trials. Inconsistency in behavioral responses (i.e., intraindividual 
variability) has received growing attention as an important marker of cognitive 
dysfunction, having been associated with poorer executive function in adults aged 64-92 
(Yao, Stawski, Hultsch, & MacDonald, 2016) as well as in individuals with PD (de Frias, 
Dixon, Fisher, & Camicioli, 2007). Intraindividual variability is also associated with 
dysfunctional activation of neural networks such as the default mode network; failures in 
deactivating the default mode network during a cognitive task may result in competing 
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neural activity that ultimately results in inconsistent behavioral responses (Kelly, Uddin, 
Biswal, Castellanos, & Milham, 2008). These findings on intraindividual variability 
parallel those in PD, including changes in frontal-lobe morphology (Braak et al., 2003; 
Tessa et al., 2014), the well-established reduction in dopaminergic neurons, and 
dysfunctional activation of the default mode network (Putcha et al., 2015). Accordingly, 
unstable spatial judgments may be an index of attentional-executive dysfunction, a 
possibility that was corroborated in our study by the Fisher’s r-to-z correlations that 
indicated a PD-specific association between the size of the standard deviation on the 
landmark test (that is, extent of performance variability) and performance on tests of 
frontal-executive function: spatial span forward and backward, Trail Making Test A and 
B, Stroop Color-Word reading, and phonemic fluency. Further, PD-specific correlations 
were found between mean percent bias and performance on several measures of attention 
and executive function: spatial span forward and backward, TMT-B, and phonemic 
fluency. Together, the pattern of behavior observed in PD, characterized by unstable 
perceived center of space and by the correlation of the extent of spatial bias with 
attentional-executive function, provides support for the hypothesis that dynamic spatial 
judgment requires the integrity of frontal-executive cortical networks.  
To our knowledge, this study is the first to consider the consistency of perceived 
center in PD. PD spatial judgment was marked by an unstable perceived center relative to 
the control group, and this occurred regardless of hemifield of initial stimulus 
presentation, although the average performance on right-side trials was more accurate 
(less biased) than for the left-side trials. The only LPD-RPD difference occurred for 
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standard deviation on right-side trials: perceived center for LPD was less stable (larger 
standard deviation) than for RPD, though we did not observe an LPD hemineglect (as in 
overall rightward spatial bias).  
The relation between a larger standard deviation of bias and attention-executive 
function has implications for mechanisms of spatial dysfunction in PD. For example, the 
orientation/estimation hypothesis suggests that perceived center is dependent upon the 
interaction of attention and line estimation. Orienting attention to one end of a line 
promotes an inaccurate estimation of line length, whereby underestimations result in 
undershooting center (bias toward left of center) and overestimations result in 
overshooting center (bias toward right of center) (Mennemeier et al., 2005). Though 
deficiencies in orienting attention and estimating line length may be characteristic of 
unilateral spatial neglect, such effects are not exclusive to hemineglect (Mennemeier, 
Vezey, Chatterjee, Rapcsak, & Heilman, 1997; Mennemeier, Vezey, Lamar, & Jewell, 
2002). The pathology of PD may impact the ability to effectively coordinate attention and 
line estimation. In the current experimental paradigm, directing attention to the left or 
right had a substantial effect on perceived center, suggesting that the experimental 
stimulus may have oriented attention in such a way that promoted an inaccurate 
estimation of the length and hence the center of the line.  
These results together offer insight into how attentional and executive dysfunction 
in PD may interfere with the capacity for accurate spatial judgments. PD is marked by 
striatal dysfunction that disturbs cortical-subcortical circuitry (Putcha et al., 2015, 2016), 
and these functional disconnections have cognitive, motor, emotional, and behavioral 
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consequences, including for spatial processing (Cronin-Golomb, 2010). Spatial 
exploration depends on the integration of visual information from the retina and occipital 
cortex with retinotopically organized maps of visual space in the dorsal parietal and 
frontal cortices (Macaluso, 2010). Further, effective spatial exploration requires scanning 
and selective processing of task relevant information and the ability to re-orient attention 
in a constantly changing environment (Cronin-Golomb & Amick, 2001). The dorsal 
fronto-parietal network (dFP; intraparietal sulcus, dorsal premotor cortex) and the ventral 
fronto-parietal network (vFP; inferior frontal gyrus, frontal operculum) are involved in 
attending to relevant information in a goal-directed manner (dFP), and flexibly adjusting 
to unexpected changes in the environment (vFP) (Macaluso, 2010). The Landmark task 
such as used in the present study has been associated with neural activity in the superior 
and inferior parietal lobes, visual processing areas, the cerebellar vermis, left cerebellar 
hemisphere, anterior cingulate, and the prefrontal cortex (Fink, Marshall, Weiss, Toni, & 
Zilles, 2002), which may be affected in PD (Martinu & Monchi, 2013; Pan, Song, & 
Shang, 2012; Sterling, Lewis, Du, & Huang, 2016). The role of functional connectivity in 
spatial processing is also noteworthy. Because disturbances of functional connectivity are 
characteristic of PD (Luo et al., 2015) and have an impact on cognitive function (Putcha 
et al., 2015, 2016), there is reason to expect that spatial bias may be a product of 
disrupted functional connectivity. The present study points to the contribution of 
attentional-executive dysfunction to lateral bias during dynamic spatial processing in PD.  
We provide novel behavioral evidence of spatial dysfunction in PD, with a large 
sample of non-demented participants. Examination of a more severe sample will 
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determine if the progression of PD promotes even more marked challenges to spatial 
judgment, including in extent of bias and inconsistency of response. Imaging studies of 
the contribution of frontal-executive networks to dynamic spatial judgment would 
provide valuable corroboratory evidence for breakdowns relevant to PD function. The 
topic is important because visuospatial dysfunction in PD limits the ability to manage 
basic spatial processes such as depth perception, figure/ground detection, motion 
perception, map reading, and allocentric and egocentric spatial judgments, all of which 
are critical to engaging with the environment (Amick, Miller, Neargarder, & Cronin-
Golomb, 2012). Individuals with PD often bring these concerns to their physician 
(Davidsdottir et al., 2005). The combined effect of visual symptoms and other PD 
symptoms may have an important contribution to quality of life. For example, gait 
dysfunction is a major determinant of quality of life and is often considered a core 
characteristic of PD in the motor domain, but it has been shown that visuospatial 
impairment drives navigational difficulties that limit mobility and may have a stronger 
influence on gait than motor symptoms (Davidsdottir et al., 2008; Ren et al., 2015; 
Young et al., 2010). Deficits in visual attention and visuospatial function also predict 
driving safety in PD (Amick, Grace, & Ott, 2007; Crizzle, Classen, & Uc, 2012; Uc, 
Rizzo, Anderson, & Dawson, 2016; Uc et al., 2009). In all, the impact of visual/spatial 
deficits on daily function in PD is debilitating, and further research on its nature and 
neural underpinnings may lead to more effective treatments than are currently available 
for this common PD symptom. 
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Tables and Figures 
Table 4  
Participant Characteristics 
Variable PD 
(n=79) 
LPD 
(n=42) 
RPD 
(n=37) 
NC 
(n=67) 
Significance 
(PD:NC) 
Age  
(years) 
 
65.0 (6.9) 64.4 (7.6) 65.6 (6.3) 62.9 (8.7) NS 
Education  
(years)  
17.4 (2.1) 17.5 (2.2) 17.4 (2.1) 17.1 (2.2) NS 
Women:Men  35:44 19:23 16:21 40:27  NS 
Purdue Pegboard 
(left hand) 
 
11.2 (2.4) 11.8 (2.5) 10.7 (2.2)  14.7 (1.9) p<.01 
Purdue Pegboard 
(right hand) 
 
11.1 (2.4) 11.0 (2.6) 11.1 (2.4)  14.1 (1.8) p<.01 
Beck Anxiety 
Inventory  
7.1 (5.1) 7.2 (5.5) 7.0 (4.7)  1.8 (2.7) p<.01 
Beck Depression 
Inventory-II 
 
7.0 (4.7) 6.8 (5.1) 7.2 (4.4)   3.1 (3.5) p<.01 
Geriatric 
Depression Scale 
 
5.6 (3.8) 5.3 (3.5) 5.9 (4.0)  3.2 (3.4) p<.01 
UPDRS Total 
  36.6 (14.9) 36.4 (14.7) 36.8 (15.3) - - 
UPDRS Motor 
Score  
 21.0 (9.8) 20.9 (8.9) 21.1 (10.7) - - 
PD Duration  
(years)  
6.3 (4.4)  5.7 (4.5) 6.9 (4.3) - - 
H&Y  
(median, range)  
 2 (1-3) 2 (1-3) 2 (1-3) - - 
LED  
(mg/day)  
 539.4 
(335.6) 
538.3 
(357.5) 
540.3 
(319.4) - - 
______________________________________________________________________________ 
PD = Parkinson's disease; NC = Normal control participants. UPDRS = Unified Parkinson's 
Disease Rating Scale; H&Y = Hoehn & Yahr stage; LED = Levodopa equivalent dosage. Values 
presented are means (standard deviations), unless otherwise indicated. LPD-RPD matched on all 
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variables except Purdue Pegboard (left; LPD<RPD; p<.04); PD-NC difference was significant for 
Purdue Pegboard, BAI, BDI, GDS (all variables; p<.01); ANOVA with NC-LPD-RPD was 
significant for Purdue Pegboard, BAI, BDI, GDS (all variables; p<.01); Direct comparisons of 
LPD-NC, RPD-NC showed p<.01 for all these variables except GDS (p<.02 for LPD). 
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Table 5 
Mean Percent Bias 
Main Effect of Group: PD versus NC 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Total* 
PD -.11 (.89) 4.85 
(1, 144) 
.03 .03 
NC .18 (.67) 
LM Left**  
PD -1.06 (1.08) 11.54 
(1, 144) 
.07 .0009 
NC -.51 (.86) 
LM Right 
PD .82 (1.06) 0.17 
(1, 144) 
.001 .68 
NC .88 (.81) 
Main Effect of Hemifield: Left versus Right 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Left, LM 
Right** 
Left -.81 (1.02) 300.74 
(1, 144) 
.68 .0001 
Right .85 (.95) 
Interaction Effect: Group by Hemifield 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Left, LM 
Right** 
-- -- 6.74 
(1, 144) 
.05 .01 
-- -- 
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Main Effect of Group: NC, LPD, RPD 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Total* 
NC .18 (.67) 
3.32 
(2, 143) 
.04 .04 LPD -.24 (.93) 
RPD -.0004 (.85) 
LM Left**  
NC -.51 (.86) 
5.86 
(2, 143) 
.08 .004 LPD -1.12 (1.18) 
RPD -1.01 (.10) 
LM Right 
NC .88 (.81) 
1.24 
(2, 143) 
.02 .294 LPD .64 (.89) 
RPD .97 (1.18) 
Main Effect of Hemifield: Left versus Right 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Left, LM 
Right** 
Left -.81 (1.02) 310.59 
(1, 143) 
.69 .0001 
Right .85 (.95) 
Interaction Effect: Group by Hemifield 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Left, LM 
Right* 
-- -- 3.72 
(2, 143) 
.05 .03 
-- -- 
 * p<.05; ** p<.01 
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Table 6 
Standard Deviation 
Main Effect of Group: PD versus NC 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Total** 
PD 1.30 (.60) 11.93 
(1, 144) 
.08 .0007 
NC .97 (.54) 
LM Left**  
PD .75 (.29) 13.95 
(1, 144) 
.09 .0002 
NC .56 (.30) 
LM Right**  
PD .78 (.41) 13.10 
(1, 144) 
.08 .0004 
NC .56 (.29) 
Main Effect of Hemifield: Left versus Right 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Left, LM Right 
Left .66 (.31) .153 
(1, 144) 
.001 .70 
Right .68 (.37) 
Interaction Effect: Group by Hemifield 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Left, LM Right 
-- -- .260 
(1, 144) 
.002 .61 
-- -- 
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Main Effect of Group: NC, LPD, RPD 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Total** 
NC .97 (.54) 
5.97 
(2, 143) 
.08 .003 LPD 1.28 (.51) 
RPD 1.32 (.68) 
LM Left**  
NC .56 (.30) 
6.93 
(2, 143) 
.09 .001 LPD .74 (.29) 
RPD .75 (.29) 
LM Right**  
NC .56 (.29) 
9.33 
(2, 143) 
.12 .0002 LPD .87 (.46) 
RPD .69 (.34) 
Main Effect of Hemifield: Left versus Right 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Left, LM Right 
Left .66 (.31) .451 
(1, 143) 
.003 .50 
Right .68 (.37) 
Interaction Effect: Group by Hemifield 
Task Group Mean (SD) 
F-value 
(df) 
eta-squared p-value 
LM Left, LM Right 
-- -- 2.44 
(2, 143) 
.033 .09 
-- -- 
 * p<.05; ** p<.01 
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Table 7 
Cognitive Assessment 
Task PD (n=79) 
LPD 
(n=42) 
RPD 
(n=37) 
NC 
(n=67) 
Significance 
(PD:NC) 
Digit Span Forward  10.63 
(2.10) 
10.65 
(1.70) 
10.62 
(2.41) 
10.88 
(2.37)  
.003 
Digit Span Backward 7.63  
(2.36)  
7.84 
(2.44) 
7.45 
(2.30) 
 8.84 
(2.42) 
N/S 
Spatial Span 
Forward 
7.81  
(1.82)  
7.83 
(1.93) 
7.79 
(1.74) 
 7.67 
(1.79) 
N/S 
Spatial Span 
Backward 
7.30  
(1.94)  
7.17 
(1.64) 
7.41 
(2.19) 
 7.43 
(1.60) 
N/S 
Trail Making Test – 
Part A 
32.61 
(8.91)  
31.30 
(8.99) 
33.78 
(8.80) 
  26.40 
(6.47) 
<.0001 
Trail Making Test – 
Part B 
78.23 
(34.79)  
75.98 
(35.10) 
80.25 
(34.88) 
58.05 
(20.26) 
<.0001 
Stroop Color-Word 35.18 
(9.99) 
36.29 
(9.48) 
34.18 
(10.45) 
41.72 
(8.32) 
<.0001 
Phonemic Fluency 42.66 
(9.77) 
42.04 
(9.99) 
43.21 
(9.69) 
51.25 
(12.78) 
<.0001 
  Values presented are means (standard deviations), unless otherwise indicated. 
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Table 8 
Correlations 
 
Group: PD 
Task (N) 
LM LEFT LM RIGHT LM SD 
r-value 
(Fishers r-to-z) 
r-value 
(Fishers r-to-z) 
r-value 
(Fishers r-to-z) 
DS Forward (N=79) 0.08 (0.34) 
-0.13 
(0.10) 
-.23* 
(0.06) 
DS Backward (N=79) -0.05 (0.46) 
-.25* 
(0.09) 
-.24* 
(0.11) 
SS Forward (N=64) .40
** 
 (0.02)* 
-0.07 
(0.27) 
-.45** 
   (0.00)** 
SS Backward (N=64) .37
** 
 (0.03)* 
-0.002 
(0.18) 
-.40** 
 (0.05)* 
TMT-A (N=70) -.24
* 
(0.16) 
0.13 
(0.20) 
.40** 
(0.02)* 
TMT-B (N=70) -.29
** 
 (0.01)* 
0.13 
(0.10) 
.46** 
   (0.00)** 
Stroop Color-Word (N=74) 0.18 (0.06) 
-0.18 
(0.36) 
-.35** 
 (0.03)* 
FAS (N=64) .38
** 
   (0.01)** 
-0.01 
(0.39) 
-.40** 
   (0.01)** 
 
Group: NC 
 
Task (N) 
LM LEFT LM RIGHT LM SD 
r-value r-value r-value 
DS Forward (N=67) 0.01 0.09 0.03 
DS Backward (N=67) -0.03 -0.04 -0.04 
SS Forward (N=54) 0.03 0.04 0.09 
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 * p<.05; ** p<.01 
  
SS Backward (N=54) 0.04 -0.17 -0.11 
TMT-A (N=62) -0.06 -0.02 0.07 
TMT-B (N=62) 0.12 -0.1 -0.17 
Stroop Color-Word (N=67) -0.08 -0.12 -0.05 
FAS (N=54) -0.06 0.04 0.01 
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CHAPTER 4:  STUDY THREE | THE IMPACT OF MOTOR SYMPTOMS ON 
SELF-REPORTED ANXIETY IN PARKINSON’S DISEASE  
Introduction 
Mood disturbances are prevalent in PD (Broen, Narayen, Kuijf, Dissanayaka, & 
Leentjens, 2016), and have a significant impact on quality of life (Hanna & Cronin-
Golomb, 2012). Approximately 20-40% of individuals with PD experience major 
depression and about 40% experience clinically significant anxiety (Aarsland, Marsh, & 
Schrag, 2009; Lieberman, 2006; Pontone et al., 2009; Reynolds, Otto, Ellis, & Cronin-
Golomb, 2016; Veazey, Ozlem Erden Aki, Cook, Lai, & Kunik, 2005; Walsh & Bennett, 
2001). Diagnosis and treatment of mood disorders, especially anxiety disorders, is 
complicated by the complex motor and non-motor symptomatology of PD.  
The neuropathology of PD gives rise to anxiety – that is, it is intrinsic to the 
disease (Chen & Marsh, 2014) – and the individual’s response to progressive disease 
symptoms may additionally elicit or exacerbate mood dysfunction (Soundy, Stubbs, & 
Roskell, 2014). Anxiety may occur independently of motor symptoms (Mondolo et al., 
2007) or may occur simultaneously (Leentjens et al., 2012). Disease-specific anxiety can 
develop, such as apprehension toward physical symptoms (e.g., freezing of gait) or the 
stigma of being perceived as physically disabled (Stanley-Hermanns & Engebretson, 
2010). Such experiences may compound the limitations that the disease imposes on 
independence and quality of life (e.g., social withdrawal) (Pachana et al., 2013). Mood 
disorders in PD are underdiagnosed (Pontone et al., 2009; Prediger, Matheus, 
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Schwarzbold, Lima, & Vital, 2012; Shulman, Taback, Rabinstein, & Weiner, 2002) and 
few treatments exist (Chen & Marsh, 2014; Djamshidian & Friedman, 2014).  
Misinterpreting anxiety symptoms as PD motor symptoms, or vice versa, can 
raise the risk of mismanaging the complex symptomatology of PD. For example, anxiety 
measures often contain items that can represent either genuine mood symptoms, or motor 
or other physical symptoms of PD – muscle tension, fatigue, concentration deficits, sleep 
difficulties, shakiness. In the normative samples from which these measures were 
derived, such symptoms are typically consequences of mood disturbances. In PD, these 
symptoms may manifest independently of mood, or may occur in conjunction with mood 
disturbances. Accordingly, common anxiety measures may inaccurately assess mood 
symptoms in PD, and despite their widespread use in research and clinical evaluations, 
they lack clinimetric support for use in PD (reviewed in Leentjens et al., 2008).  
The purpose of this study was to assess the impact of motor symptoms on self-
reported anxiety in mild to moderate PD. The Beck Anxiety Inventory (BAI) (Beck & 
Steer, 1990) is a standard measure of anxiety that was developed with the intention of 
reliably distinguishing anxiety from other mood disorders in a psychiatric population 
(i.e., discriminant validity). The BAI has been widely used to assess anxiety in PD, and 
concerns have been raised regarding construct validity and potential under-recognition of 
anxiety in PD (Leentjens et al., 2011). Considering the widespread use of the BAI, an 
understanding of the impact of motor symptoms on self-reported anxiety would either 
increase confidence in its continued use or instead promote the selection of more PD-
specific anxiety measures.  
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We hypothesized that a factor analysis of the BAI would reveal a PD motor factor 
consisting of items that also reflect hallmark motor symptoms, and that endorsement of 
motor symptoms would affect self-reported anxiety scores. We expected that tremor 
severity would impact BAI scores, and that BAI motor items would be significantly more 
elevated for those with moderate to severe tremor than for those with absent or mild 
tremor. We also assessed a group of age-matched individuals without PD in order to ask 
the question of whether anxiety in PD was still elevated after considering the motor items 
on the measure.  
Hypotheses 
Hypothesis 1: PD-motor symptoms would group together on common mood 
measures. 
Hypothesis 2: Endorsement of motor-like symptoms, specifically tremor 
dominant symptoms, would inflate self-reported mood. 
Hypothesis 3: When compared to age-matched control participants, in PD the 
endorsement of motor symptoms would more strongly contribute to mood scores. 
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Method 
Participants 
We assessed 100 individuals with idiopathic PD (45 women, 55 men) and 74 age- 
and education- matched normal control adults (NC) (42 women, 32 men) (Table 9). All 
procedures were approved by the Institutional Review Board of Boston University, and 
consent was obtained according to the Declaration of Helsinki.  
PD participants were recruited through the Parkinson’s Disease Clinic at Boston 
Medical Center and through other community resources including Fox Trial Finder and 
PD support groups. NC participants were recruited from the general community. For both 
groups, exclusion criteria included coexisting serious chronic illness (including 
psychiatric or neurological); use of psychoactive medications besides antidepressants and 
anxiolytics in the PD group; use of any psychoactive medication in the NC group; history 
of intracranial surgery, traumatic brain injury, and alcoholism or other drug abuse. All 
participants scored above 26 on the modified form of the Mini-Mental State Examination 
(Stern et al., 1987), on conversion to standard MMSE scoring.  
Diagnosis of idiopathic PD was made by the participants’ neurologists, using 
United Kingdom Parkinson’s Disease Society Brain Bank clinical diagnostic criteria 
(Hughes et al., 1992). The participants met clinical criteria for mild to moderate disease, 
with a modified Hoehn and Yahr stage range of 1-3 (Goetz et al., 2004). The sample 
included 13 in stage 1, 17 in stage 1.5, 37 in stage 2, 15 in stage 2.5, and 18 in stage 3. 
Disease severity was assessed with the Unified Parkinson’s Disease Rating Scale (Fahn 
& Elton, 1987; Levy et al., 2005). The mean UPDRS total score was 37.1 (SD = 15.3), 
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with a mean motor score of 21.4 (SD = 10.3). Average disease duration was 6.1 years 
(SD = 4.3). Levodopa equivalent dosages (LED), available for all but two participants 
with PD, were calculated according to Tomlinson and colleagues’ conversion formulae 
(Tomlinson et al., 2010). All participants were tested in the “on” medication state. 
Subjective quality of life was measured with the 39-item Parkinson’s Disease 
Questionnaire (Peto et al., 1995). The participants completed the UPDRS at the same 
time as completing the self-report questionnaires. 
For both the PD and NC groups, mood was assessed with the Beck Anxiety 
Inventory (Beck & Steer, 1990) and the Beck Depression Inventory-II (Beck et al., 1996). 
No participant had a clinical diagnosis of anxiety. 
 
Procedures 
Participants completed self-report questionnaires at Boston University’s Vision and 
Cognition Laboratory: 
Beck Anxiety Inventory (BAI): Standard 21-item anxiety measure (Beck & Steer, 1990)  
Beck Depression Inventory (BDI): Standard 21-item depression measure (Beck, Steer, & 
Brown, 1996). 
Parkinson’s Disease Questionnaire-39 (PDQ-39): Standard 39-item measure of 
subjective quality of life in PD (Peto, Jenkinson, Fitzpatrick, & Greenhall, 1995).  
Unified Parkinson’s Disease Rating Scale (UPDRS): Standard measure of PD severity 
assessing: (A) Mentation, Behavior, and Mood; (B) Activities of Daily Living (ADL); (C) 
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Motor Examination (observer rated); (D) Complications (Fahn & Elton, 1987; Levy et 
al., 2005).  
To assess tremor symptoms, UPDRS tremor item (item #16) was used to 
characterize participants who reported absent-to-slight tremor (score of 0 or 1; n = 65) or 
moderate-to-severe tremor (score of 2 or 3; n = 35). The UPDRS tremor items from the 
objective motor examination (items 20-26) were summed and used as a continuous 
measure for analyses.  
 
Statistical analyses 
To assess the loading of PD motor symptoms, a factor analysis was conducted 
using principal axis factoring and varimax rotation.  
Items were considered if they had a coefficient greater than .40 (Costello & 
Osborne, 2011). We hypothesized that BAI symptoms that represented motor symptoms 
of PD (shaky, hands trembling, unsteady) would load onto the same factor.  
To assess the impact of these motor items on self-reported mood, comparisons 
were made between the total score and the total score minus PD motor symptoms (i.e., 
BAI modified). The following procedures were used to determine the impact of these 
motor items on mood scores: 
A mixed design repeated measures ANOVA with one between group variable 
(PD vs NC) and one within group variable (BAI total vs BAI modified) was used, with 
specific interest in the interaction effect. If motor items had a greater impact on total 
scores for PD than for NC, removal of these items would result in a significant 
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interaction. The same analysis was conducted according to tremor severity (absent-slight 
tremor vs. moderate-severe tremor) to assess whether tremor severity had an impact on 
self-reported anxiety specifically for PD.  
Mediation analyses were conducted with the SPSS mediation modelling software, 
PROCESS (Hayes, 2013), to consider whether motor-like items mediated the difference 
between PD and NC on total mood scores. The analysis considered the total effect of 
group on anxiety (BAI), and the indirect effect mediated by BAI motor items. A 
bootstrap estimation approach with 1,000 samples was used to measure the indirect effect 
(Shrout & Bolger, 2002), with 95% confidence intervals. The indirect effect was 
considered significant when the 95% confidence intervals did not contain zero (Preacher 
& Hayes, 2004). A significant mediator was indicated when the total effect was 
significant, the indirect effect was significant, and the confidence intervals of the direct 
effect contained zero (Hayes, 2013).  
For PD only, one-tailed Pearson correlations were used to assess the relation 
between BAI motor symptoms and the following disease characteristics: 1) objective 
tremor severity (UPDRS #20-26), 2) UPDRS motor severity (UPDRS Section C), 3) 
disease severity (H&Y), 4) quality of life (PDQ-39), 5) depression (BDI-II), and 6) 
disease duration. To account for multiple comparisons, alpha was set at .01. Follow-up 
partial correlations were conducted, controlling for motor-like symptoms, and Fisher’s r-
to-z transformations were conducted to determine if controlling for motor symptoms had 
a significant impact on the relation between mood and disease characteristics. Analyses 
were performed with SPSS 20.0 (SPSS, Inc., Chicago, IL). 
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Results 
The BAI factor analysis yielded a 5-factor solution, cumulatively accounting for 
47.2% of the variance in the BAI. Three items were not included in the analysis: 
“numbness or tingling” and “feelings of choking” did not reach a coefficient of .4, and 
none of the participants endorsed “terrified”. The PD motor items that were selected a 
priori for consideration loaded onto the first factor, which accounted for 11.3% of the 
variance in the BAI. The five factors consisted of the following BAI items (Table 10):  
[Factor 1]: Shaky, hands trembling, unsteady, wobbliness in legs, nervous  
[Factor 2]: Scared, fear of the worst happening, fear of dying  
[Factor 3]: Faint, dizzy or lightheaded, fear of losing control, heart pounding or racing 
[Factor 4]: Sweating, feeling hot, face flushed   
[Factor 5]: Indigestion or discomfort in abdomen, unable to relax, difficulty breathing 
 
Interaction Effect: BAI by Group 
Removing the BAI motor factor resulted in a significant reduction in the BAI for 
both PD [t(99) = 13.54, p < .0001] and NC [t(73) = 4.89, p < .0001], but the reduction 
was significantly greater for PD than NC [F(1, 172) = 86.88, p < .0001, ŋ2 =  .34] (Figure 
3). PD had higher scores than NC on BAI total [t(164.16) = 8.03, p < .0001], the BAI 
motor factor [t(133.81) = 10.39, p < .0001], and the BAI modified [t(171.36) = 4.93, p < 
.0001].  
We compared BAI scores for those with absent-slight vs. moderate-severe tremor 
(UPDRS tremor item). Removing the BAI motor factor resulted in a significant reduction 
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in the BAI in both PD groups: absent-slight tremor [t(64) = 10.02, p < .0001] and 
moderate-severe tremor  [t(34) = 9.84, p < .0001]. The reduction was significantly greater 
for those with moderate-severe tremor [F(1, 98) = 7.73, p < .007, ŋ2 =  .07]. Those with 
moderate-severe tremor had higher scores on the BAI motor factor [t(98) = 2.82, p < 
.006] but did not differ from the absent-slight tremor group on BAI total [t(98) = 1.34, p 
< .18] or BAI modified [t(98) = .17, p < .86]. 
 
Mediation Analysis 
The results of the mediation analysis are presented in Table 11. When the BAI 
motor factor was entered as a mediator of group and BAI total scores, the total effect was 
significant [B = -4.78, p < .0001], the indirect effect was significant [B = -4.23, 95% CI:  
-5.60, -3.15], and the direct effect approached zero [B = -0.54, 95% CI: -1.63, .55]. That 
is, the BAI motor factor fully mediated the effect of PD on BAI total scores.  
 
Correlations: Mood and Disease Characteristics 
BAI total score correlated significantly with poorer quality of life (PDQ-39), 
higher BDI-II scores, and longer disease duration (Table 12). There were additional 
trends for correlations of BAI total score with poorer motor function (UPDRS motor 
score) and with tremor severity (sum of tremor items from the UPDRS motor section). 
The BAI motor factor related to tremor severity, poorer motor function, poorer quality of 
life, and greater depression. There were additional trends for correlations with greater 
disease severity and greater disease duration.  
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For the partial correlations controlling for the BAI motor factor, the correlation 
remained significant between the BAI and quality of life, depression severity, and disease 
duration. Fisher’s r-to-z transformations indicated that the difference in the size of the 
correlation was significant for the relation between BAI and tremor severity, motor 
function, quality of life, and disease severity.  
 
Discussion 
The results of this study addressed the impact of motor symptoms on self-reported 
anxiety. As hypothesized, PD motor symptoms grouped together on factor analysis of the 
BAI. The BAI motor factor significantly correlated with disease characteristics – tremor 
severity, motor function (UPDRS), quality of life, and depression. The BAI total score 
correlated with poorer quality of life, higher BDI-II scores, and longer disease duration. 
Controlling for the BAI motor factor resulted in a significant decrease in the strength of 
the correlation between the BAI and quality of life. 
The impact of the BAI motor factor on BAI total scores highlights the importance 
of considering motor symptoms when measuring self-reported anxiety. After removing 
the BAI motor factor, the PD group showed a significantly greater decrease in BAI scores 
than did NC. As expected, tremor severity related to symptom report on the BAI motor 
factor; for individuals with moderate or severe tremor, the removal of BAI motor items 
had a significantly greater impact on the anxiety score than for those with absent or slight 
tremor. The BAI motor factor mediated the effect of PD on anxiety. Though PD is 
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associated with greater anxiety disturbances than seen in the general population (Broen et 
al., 2016; Reynolds et al., 2016), on the widely-used BAI the effect of PD was 
significantly influenced by their scores on motor items. BAI scores remained 
significantly higher for PD than NC even when accounting for motor items, indicating 
that the BAI does measure more anxiety (apart from motor disturbances) in PD than in a 
non-PD population. In another study that assessed the BAI in a sample of 294 individuals 
with PD, a single 6-item affective factor was independent of motor or somatic symptoms 
(Rutten et al., 2015).  
The question remains as to whether those with PD erroneously endorse motor 
symptoms as mood symptoms, or whether they are endorsing genuine mood disturbance 
on these motor items, or whether there is an interaction between mood and motor 
symptoms. It is possible that these motor symptoms operate independently of mood and 
offer a more general index of disease severity. It is also possible that the motor symptoms 
operate in conjunction with mood, exacerbating or causing mood disturbances. For 
example, the manifestation of motor symptoms may promote social withdrawal (Soundy, 
Stubbs, et al., 2014), thereby promoting anxiety and depression. Interactive motor-mood 
effects such as anxiety related to motor fluctuations may affect motor and mood 
disturbance (Leentjens et al., 2012). Future work is needed in order to address these 
questions of causes, mechanisms, and treatment targets. In particular, a wider range of 
individuals should be sampled than are described in the present study, which was limited 
to participants with mild to moderate PD who did not have a clinical diagnosis of a mood 
disorder. Nevertheless, PD motor symptoms significantly contributed to anxiety scores in 
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this sample, suggesting that their impact may be even stronger in a sample with more 
severe disease.  
The complexity of motor-mood symptoms in PD is noteworthy in its potential 
contribution to how the disease is understood and managed. Misinterpretation of mood 
symptoms may result in symptom mismanagement. For example, there are a host of 
adverse side effects associated with pharmacological treatments for neuropsychiatric 
symptoms in PD (Connolly & Fox, 2014), and unnecessarily introducing such treatments 
may have a negative impact on quality of life. In contrast, misinterpreting mood as motor 
symptoms may result in entirely overlooking mood symptoms. One study of 362 
individuals with PD found that clinicians who completed a self-report questionnaire on 
behalf of their patients endorsed less anxiety than individuals with PD who completed the 
same self-report questionnaire (Forjaz et al., 2013). In this instance, failure to recognize 
mood symptoms in PD can result in untreated mood dysfunction, which is a significant 
determinant of quality of life.  
Continued consideration of mood dysfunction in PD, and its measurement, is 
warranted in order to direct proper assessment, diagnosis, and treatment. Despite the well 
documented prevalence and burden of mood dysfunction in PD, there remains 
widespread use of mood measures lacking psychometric validation for PD. The 
Movement Disorders Society has noted that popular anxiety scales lack sufficient 
psychometric properties for use in PD and can only be classified as “suggested” rather 
than “recommended” measures of mood in this population (Leentjens et al., 2008). It has 
more recently been suggested that the BAI and the Hamilton Anxiety Rating Scale 
82 
 
together provide a valid, multi-domain assessment of anxiety including generalized 
anxiety, non-specific somatic symptoms, respiratory symptoms, and cardiovascular 
symptoms (Martinez-Martin et al., 2013). Leentjens et al. (2014) extended this work by 
creating the 12-item Parkinson’s Anxiety Scale (Leentjens et al., 2014) to assess 
persistent anxiety, episodic anxiety, and avoidance behavior; the items assessing 
persistent and episodic anxiety were found to have acceptable reliability and validity. The 
Parkinson’s Anxiety Scale showed better reliability than the BAI (Forjaz et al., 2013), 
and was found to be more suitable for assessing anxiety in PD (Dissanayaka, Torbey, & 
Pachana, 2015). The results of the present study further demonstrate the importance of 
employing mood measures specifically validated for individuals with PD; failure to do so 
may yield uninterpretable results, and ultimately raise the risk of mismanaging PD 
symptoms. Future research might consider determining the barriers to assessing PD-
specific mood measures. The use of valid measures and efficacious treatments for mood 
dysfunction will have important implications for the care of individuals with PD and for 
the enhancement of their quality of life.  
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Tables and Figures 
Table 9 
Participant characteristics 
Variable  Group N Mean SD p-value 
Age 
PD 100 65.0 7.1 
0.30 
NC 74 63.7 9.2 
Women:Men 
PD 45:55 -- -- 
0.13a 
NC 42:32 -- -- 
Education 
PD 100 17.4 2.2 
0.39 
NC 74 17.1 2.2 
BAI 
PD 100 6.8 4.9 
< .0001** 
NC 74 2.0 2.9 
BDI-II 
PD 93 7.1 4.7 
< .0001** 
NC 74 3.2 3.7 
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PD Duration      
 (years) PD 100 6.1 4.3 -- 
Hoehn & Yahr    
(median, range) PD 100 2 (1-3)
b -- -- 
UPDRS Total PD 100 37.1 15.3 -- 
UPDRS Motor Score PD 100 21.4 10.3 -- 
PDQ-39Total PD 100 34.6 19.5 -- 
LED (mg/day) PD 98  531.1 339.5 -- 
**Significant group difference 
aChi square test; bMedian, range.  
PD = Parkinson's disease; NC = Normal control participants; UPDRS = Unified 
Parkinson's Disease Rating Scale; H&Y = Hoehn & Yahr stage; LED = Levodopa 
equivalent dose; PDQ-39 = 39-item Parkinson’s Disease Questionnaire; BAI = Beck 
Anxiety Inventory; BDI-II = Beck Depression Inventory-II; Values presented are means 
(standard deviations), unless otherwise indicated. The last six measures were specific to 
PD.  
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Table 10 
Results of Factor Analysis of the Beck Anxiety Inventory 
 
Factor BAI Items 
Factor 1: Shaky, hands trembling, unsteady, wobbliness in legs, nervous 
Factor 2: Scared, Fear of the worst, fear of dying 
Factor 3: Faint, dizzy or lightheaded, fear of losing control, heart pounding 
Factor 4: Sweating, feeling hot, face flushed 
Factor 5: Indigestion, unable to relax, difficulty breathing 
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Table 11 
Mediation analyses 
 
Model 1 IV: Group DV: BAI Total Mediator: BAI Motor Factor 
  Path B SE t p 95% CI 
  a -2.51 .27  -9.28 <.0001** -3.04, -1.97  
  b 1.69 .13  13.31 <.0001** 1.44, 1.94 
total effect c -4.78 .64 -7.46 <.0001** -6.04, -3.52  
direct effect c - (a*b) -0.54  .55  -0.98 .33 -1.63, 0.55  
indirect effect c' -4.23 .63      -5.60, -3.15 
*Significant group difference 
BAI = Beck Anxiety Inventory; IV = independent variable; DV = dependent variable; B 
= unstandardized regression coefficient; SE = Standard Error; t = t-value; 95% CI = 95 
percent confidence interval 
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Table 12 
Correlations between BAI scores and demographic/disease characteristics 
 
  
 
UPDRS 
Tremor  
 
UPDRS 
Motor  
 
PDQ-39 
total  
H&Y BDI-II Duration Age 
BAI 
Total 
r 0.18* 0.17* 0.68** 0.15 0.55** 0.26** -0.14 
p 0.03 0.04 0.000 0.07 0.000 0.005 0.09 
BAI 
Motor 
Factor 
r 0.34** 0.34** 0.52** 0.21* 0.44** 0.18* -0.04 
p 0.000 0.000 0.000 0.02 0.000 0.04 0.34 
Correlations controlling for BAI Motor Factor 
 UPDRS Tremor 
UPDRS 
Motor 
PDQ-39 
total H&Y BDI-II Duration Age 
BAI  
Total 
r 0.05 0.04 0.62** 0.08 0.49** 0.24** -0.16 
p 0.32 0.37 0.000 0.23 0.000 0.007 0.054 
r-to-za 
p-value 
2.02* 
0.02 
2.06* 
0.02 
1.82* 
0.03 
1.94* 
0.03 
1.61 
0.05 
0.49 
0.31 
0.14 
0.44 
* p<.05, ** p<.01 
aFisher’s r-to-z transformation.  
PD = Parkinson's disease; NC = Normal control participants; UPDRS = Unified Parkinson's 
Disease Rating Scale; H&Y = Hoehn & Yahr stage; LED = Levodopa equivalent dose; PDQ-39 = 
39-item Parkinson’s Disease Questionnaire; BAI = Beck Anxiety Inventory; BDI-II = Beck 
Depression Inventory-II 
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Figure 3 
Interaction: BAI by Group 
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Figure 4 
 
BAI-motor items mediate the effect of group on BAI scores 
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CHAPTER 5:  STUDY FOUR | PREDICTORS OF SELF-PERCEIVED STIGMA 
IN PARKINSON’S DISEASE 
Introduction 
Though PD has traditionally been characterized as a motor disorder, the burden of the 
disease extends far beyond physical limitations. Diagnosis of PD is a major life 
transition, and requires adjusting to its multifaceted demands (Gibson, 2016; Phillips, 
2006). The psychosocial adjustment to PD is significant, as individuals undergo changes 
to their self-perception and to how others perceive them (Hartley et al., 2014; Stanley-
Hermanns & Engebretson, 2010). Self-perceived stigma may result from exposure to 
negative societal attitudes toward the disease, which may ultimately foster subjective 
acceptance of these negative attitudes. Stigmatizing beliefs and experiences are common 
(Hermanns, 2013) and individuals with PD may experience decreased self-esteem, 
increased social anxiety, social withdrawal, and panic attacks (Soundy, Stubbs, et al., 
2014). They may further endorse shame and uncertainty regarding the disease, and 
experience feelings of being neglected and isolated (Birgersson & Edberg, 2004; 
Hermanns, 2013). Longstanding relationships with significant others can undergo strain 
in response to the onset and progression of PD symptoms (O'Connor E, McCabe, & Firth, 
2008). Motor symptoms such as facial masking can fuel negative social perceptions even 
among trained healthcare providers (Tickle-Degnen, Zebrowitz, & Ma, 2011). Traditional 
PD treatment approaches target progressive motor symptoms, while neglecting the 
subjective impact of the diagnosis. Failure to consider an individual’s social-emotional 
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management of PD disregards a major aspect of clinical care.  
Although research has offered qualitative descriptions of stigma in PD (Hemmesch, 
Tickle-Degnen, & Zebrowitz, 2009; Tickle-Degnen et al., 2011), quantitative evidence of 
contributing factors is limited. Neurosurgical interventions targeted toward relief of 
motor dysfunction have demonstrated a reduction in self-perceived stigma, suggesting a 
relation between motor symptoms and stigma (Ellis et al., 2008; Lyons & Pahwa, 2005; 
Nijhawan et al., 2009). Disease-specific challenges such as medication fluctuations (i.e., 
off periods) and motor complications (e.g., dyskinesias) have important psychosocial 
implications (Soundy, Stubbs, et al., 2014) and are related to self-perceived stigma 
(Lyons & Pahwa, 2005). Research on the relation between stigma and mood interventions 
in PD suggests that treating mood symptoms may reduce self-perceived stigma (Antonini 
et al., 2006).  
 Considering the complex motor and non-motor symptomatology of PD, there is 
reason to expect that stigma may manifest differently according to demographic and 
disease characteristics. For example, younger age of PD onset is associated with greater 
disease burden: motor complications, unemployment due to disability, poorer quality of 
life, depression, and greater stigmatization and marital dissatisfaction (Den Oudsten, Van 
Heck, & De Vries, 2007; Schrag, Hovris, Morley, Quinn, & Jahanshahi, 2003). Men and 
women experience PD differently (Miller & Cronin-Golomb, 2010), and current 
treatment practices underappreciate how PD impacts women (Fleming, Tolson, & 
Schartau, 2004). The conceptualization and treatment of stigma in PD is limited by an 
incomplete understanding of the contributory factors. 
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The purpose of this study was to assess the contributions of clinical and demographic 
characteristics to self-perceived stigma in PD. The following were expected to relate to 
self-perceived stigma in PD: 
Hypotheses 
Hypothesis 1: Demographic characteristics: Age and gender. Younger age would 
relate to increased self-perceived stigma, as diagnosis of PD typically results in more 
drastic life adjustments for younger individuals (Schrag et al., 2003). Women would 
endorse more stigma than men, reflecting greater societal emphasis on physical 
appearance in women (Posen et al., 2000). 
Hypothesis 2: Disease characteristics and functional impairment. Visibility of 
symptoms and severity of dysfunction would predict self-perceived stigma; hence, those 
with tremor-dominant symptoms (TD), which may be apparent during most social 
situations, would endorse more stigma than those with postural instability and gait 
disorder (PIGD), whose problems may not be as obvious to the observer in certain 
situations (as when sitting). Limits to independence as indicated by self-reported 
challenges in activities of daily living (ADLs) would predict stigma. 
Hypothesis 3: Depression. Depression is associated with negative cognitive biases 
(Barlow, 2000; Beck, 2008; Gotlib & Neubauer, 2000; Hallion & Ruscio, 2011); hence, 
depression would predict self-perceived stigma. 
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Method 
Participants 
Participants included 362 individuals with idiopathic PD (157 women, 205 men) 
who were assessed as part of two larger PD studies (Table 13). Data from 262 
participants were collected as described in Dibble et al. (2010) (Dibble et al., 2010) and 
the remaining 100 participants were assessed in Boston University’s Vision and 
Cognition Laboratory. All procedures were approved by the Institutional Review Board 
of each of the data collection sites, and consent was obtained according to the Declaration 
of Helsinki.  
Participants from the study by Dibble et al (2010) were recruited from the 
Movement Disorders Clinic at Boston Medical Center (N=76), University of Utah 
(N=38), Washington University in St. Louis (N=78) and University of Alabama (N=70). 
The 100 participants assessed in the Vision and Cognition Laboratory were recruited 
from the Movement Disorders Clinic at Boston Medical Center and other community 
resources including Fox Trial Finder and PD support groups. Inclusion criteria relevant to 
the current study consisted of a diagnosis of idiopathic PD according to the UK Brain 
Bank Criteria (Hughes et al., 1992) and a modified Hoehn and Yahr stage less than or 
equal to 4 (Goetz et al., 2004). Exclusion criteria included a diagnosis of atypical 
parkinsonism, early onset PD (<40 years of age), or previous surgical management of PD.  
The total sample had an average age of 67.0 years (SD = 8.7) and disease duration 
of 6.1 years (SD = 4.7). Median modified Hoehn & Yahr (H&Y) stage was 2 (range 1-4) 
(Goetz et al., 2004). Motor severity as measured by the Movement Disorder Society 
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Unified Parkinson’s Disease Rating Scale (MDS-UPDRS; Goetz et al., 2008) was 32.2 
(SD = 14.6). Motor symptom subtypes (Jankovic et al., 1990; Stebbins et al., 2013) 
consisted of 110 with tremor-dominant profile (TD; 30.4%), 223 characterized by 
postural instability and gait disorder (PIGD; 61.6%), and 29 indeterminate (IND; 8.0%), 
all as per time of assessment. All participants were tested while on medication, and had a 
Mini Mental Status Examination score > 24/30.  
Procedures 
Data from demographics and from disease characteristics of duration, stage 
(Hoehn and Yahr), motor severity, ADLs, and depression were analyzed with respect to 
self-perceived stigma. The measures of stigma perception, motor severity, ADLs, and 
depression are as follows. 
 Stigma perception: Parkinson’s Disease Questionnaire-39 (PDQ-39). The 
PDQ-39 is a standard 39-item measure of subjective quality of life in PD (Peto et al., 
1995). There were four items on stigma (items 23-26). These were: (#23) Felt you had to 
hide your Parkinson’s from people; (#24) Avoided situations which involve eating or 
drinking in public; (#25) Felt embarrassed in public; (#26) Felt worried about other 
people’s reaction to you. Each item was scored on a 5-point ordinal scale of 0-4 with 0 = 
never and 4 = always. Participants responded to each item with respect to their 
experiences within the last month. The scores ranged from 0-16. PDQ-39stigma scores were 
converted to a 100 point scale by multiplying the mean of the stigma items by 100, 
following the methods of Peto, Jenkinson, & Fitzpatrick, 1998 (Peto et al., 1998). 
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 Motor severity and activities of daily living: Unified Parkinson’s Disease 
Rating Scale (UPDRS). The MDS-UPDRS (Goetz et al., 2008) was administered to all 
participants in Dibble et al. (2010), and the original UPDRS (Fahn & Elton, 1987; Levy 
et al., 2005) was administered to the 100 participants recruited by the Vision and 
Cognition Laboratory of Boston University. In order to pool data across the samples, a 
standard formula was used to convert sections (B) Activities of Daily Living (ADL) and 
(C) Motor Examination (observer rated) of the UPDRS scores to the analogous MDS-
UPDRS sections, which are, respectively, (2) Motor Experiences of Daily Living and (3) 
Motor Examination (Goetz, Stebbins, & Tilley, 2012). Such conversions are not available 
for sections A and D, and therefore analyses were limited to data from sections B and C. 
Motor symptom subtype was calculated by the ratio of mean tremor to mean 
PIGD symptoms. For the original UPDRS, a ratio greater than or equal to 1.5 was 
classified as tremor dominant (TD), a ratio less than or equal to 1.0 was classified as 
postural instability and gait disorder (PIGD), and a ratio between 1.0-1.5 was classified as 
indeterminate (IND) (Jankovic et al., 1990). For the MDS-UPDRS, a ratio greater than or 
equal to 1.15 was classified as tremor dominant, a ratio less than or equal to 0.90 was 
classified as PIGD, and a ratio between 0.90-1.15 was classified as indeterminate 
(Stebbins et al., 2013). Seventeen participants had a tremor score of 0 and were classified 
as PIGD; 12 participants had a PIGD score of 0 and were classified as TD (Stebbins et 
al., 2013). No participant had scores of 0 for both tremor and PIGD symptoms. There 
were a total of 110 TD, 223 PIGD, and 29 IND. 
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Depression: Geriatric Depression Scale. This is a standard 30-item depression 
measure (Yesavage et al., 1982). Participants responded either yes or no to the experience 
of depression symptoms within the last week. The sum of all items was calculated, with a 
possible range of 0-30. Higher scores were indicative of greater depression severity. The 
GDS has proven to have high discriminant validity and internal consistency in PD (Ertan, 
Ertan, Kiziltan, & Uygucgil, 2005). 
 
Statistical Analyses 
For each variable, the mean and standard deviation were calculated. Two-tailed 
Pearson correlations were conducted with an alpha of p<.01 as significant in order to 
account for multiple correlations. Correlations between stigma and age, disease duration, 
disease stage (H&Y), motor severity (MDS-UPDRS – Part 3), activities of daily living 
(ADLs; MDS-UPDRS – Part 2), and depression (GDS) were examined. Significant 
correlates were entered as predictors in a hierarchical regression analysis with self-
perceived stigma (PDQ-39stigma) as the dependent variable. T-tests were used to assess if 
self-reported stigma was different between men and women, and between TD and PIGD. 
Because gender differences are well documented in PD (Miller & Cronin-Golomb, 2010), 
separate regressions were conducted for men and women in addition to the whole-group 
analyses.  
 Regression models were built by entering significant correlates of stigma as the 
predictors in a three-block linear regression. The order of block entry was determined 
according to the following rationale. Block 1: Age and disease duration were entered first 
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as general, non-modifiable demographic and disease characteristics; Block 2: Disease 
stage (H&Y), motor severity (MDS-UPDRS – Part 3), and activities of daily living 
(MDS-UPDRS – Part 2) were entered as PD-specific indices of disease severity; Block 3: 
depression was entered last as a non-motor feature of PD. Each successive block of 
predictors was entered to assess the predictive value of those variables above and beyond 
the preceding factors. Using an F test (α = 0.05), the significance of the r2 and r2 change 
values was examined to identify predictors of variance in stigma score.  
Mediation analyses were performed to assess whether significant predictors 
mediated the relation between PD motor dysfunction (MDS-UPDRS sections 2 and 3) 
and PDQ-39stigma. The total, direct, and indirect effect was assessed with the software 
PROCESS, which allows for modeling mediation in SPSS (Hayes, 2012). A bootstrap 
estimation approach with 1,000 samples was used to measure the indirect effect (Shrout 
& Bolger, 2002), with 95% confidence intervals. The indirect effect was considered 
significant when the 95% confidence intervals did not contain zero (Preacher & Hayes, 
2004). A predictor was considered a significant mediator when the total effect was 
significant; the indirect effect was significant; and the confidence intervals of the direct 
effect contained zero (Hayes, 2013).  
Analyses were performed with SPSS 20.0 (SPSS, Inc., Chicago, IL). 
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Results 
For the whole group, the significant correlates of PDQ-39stigma were age (p = 
.009), ADLs (p < .0001) and depression (p < .0001). The three-block linear regression 
model included (1) age, (2) ADLs, (3) depression. This full model accounted for 14.2% 
of the variance in PDQ-39stigma (r2 = .142, F = 18.99, p < .0001). Younger age (B = -.380, 
p < .0003) and higher depression scores (B = .966, p < .0001) were the only significant 
predictors of the PDQ-39stigma score.  
For women, only depression correlated with PDQ-39stigma (r = .22, p < .007), and 
this was a significant predictor of stigma, accounting for 4.8% of the variance in PDQ-
39stigma (r2 = .048, F = 7.52, B = .65, p < .007). For men, the significant correlates were 
age (p < .002), depression (p < .0001), and ADLs (p < .00005). Age (B = -.49, p < .001) 
and depression (B = 1.18, p <.001) were significant predictors of stigma and together 
accounted for 22% of the variance in PDQ-39stigma (r2 = .22, F = 18.26, p < .001).  
Self-perceived stigma was not significantly different for men and women (t(360) 
= -.44, p = .66) or for the TD and PIGD subgroups (t(325) = -1.51, p = .88). 
The results of the mediation analyses are presented in Table 13. When depression 
was entered in the mediation model for MDS-UPDRS-ADLs and PDQ-39stigma (Model 1), 
the total effect was significant [B = .49, p = .0008], the indirect effect was significant [B 
= .33, 95% CI: .18-.56], and the direct effect of MDS-UPDRS-ADLs on PDQ-39stigma 
approached zero [B = .16, 95% CI: -.12, .44], representing a decline in the strength of the 
direct effect (Figure 1). This supports depression as a full mediator of the relation 
between MDS-UPDRS-ADLs and PDQ-39stigma. In this model, the indirect effect through 
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depression accounted for a significant portion of the total effect, whereas the contribution 
of the direct effect between ADLs and stigma was not significant. In other words, the 
significant relation between challenges with ADLs and stigma perception was driven 
entirely by the relation to depression.  
When depression was assessed as a mediator of MDS-UPDRS-motor and PDQ-
39stigma (Model 2), the total effect was not significant [B = .14, p = .07], the indirect effect 
was significant [B = .15, 95% CI: .09, .25], and the direct effect was zero [B = -0.01, 
95% CI: -.16, .14]. The mediation models with age (Models 3 & 4) as the mediator did 
not support age as a significant mediator. Inclusion of age in the model enhanced the 
strength of the direct effect, though the indirect effect was not significant. In other words, 
the relation between PD motor dysfunction and stigma was primarily driven by the direct 
effect; the contribution of age was not significant. 
 
Discussion 
Self-perceived stigma in our general PD sample was predicted by younger age 
and greater depression severity. The prediction by depression held for both men and 
women, whereas the prediction by age was specific to men. The relation between PD 
ADLs and stigma was mediated by depression: as depression increased, the relation 
between PD ADLs and stigma strengthened. Contrary to expectations, disease-specific 
motor impairments were not significant predictors, nor did the severity of stigma differ 
according to gender or motor symptom subtypes.  
Depression exhibited the strongest relation to stigma, and impacted the relation 
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between ADLs and stigma. This finding is in accord with those of multiple studies 
describing depression as a prevalent, significant contributor to quality of life in PD 
(McKinlay et al., 2008; Soh, Morris, & McGinley, 2011). The relation between younger 
age and stigma is consistent with research that has demonstrated greater disease burden 
for younger individuals with PD (Schrag et al., 2003). The significant contribution to 
stigma of age and depression, and not motor impairments or gender, has implications for 
the conceptualization of stigma in PD, which has to date been limited, possibly because 
of the traditionally stronger research emphasis on the biological than on the psychosocial 
aspects of PD (Dakof & Mendelsohn, 1986; Simpson, Lekwuwa, & Crawford, 2013). 
Stigma in other neurological populations has received more attention than in PD. For 
example, extensive research has been conducted on stigma in epilepsy (Fernandes, Snape, 
Beran, & Jacoby, 2011; Jacoby, Snape, & Baker, 2005), and stigma has been recognized 
in many other neurological disorders including multiple sclerosis (Grytten & Måseide, 
2006), amyotrophic lateral sclerosis (Kang, 2008), dystonia (Papathanasiou, MacDonald, 
Whurr, & Jahanshahi, 2001; Rinnerthaler, Mueller, Weichbold, Wenning, & Poewe, 
2006), Huntington’s disease (Williams, Erwin, et al., 2010), and Alzheimer’s disease 
(Jolley & Benbow, 2000). Each of these neurological conditions is marked by limitations 
in the individual’s ability to conceal and control symptoms, which can subsequently 
promote feelings of shame toward the disease and its potential consequences (i.e., felt 
stigma) and risk of being treated as outside of societal norms (i.e., discrimination, enacted 
stigma) (Fernandes et al., 2011). By contrast, few attempts have been made to advance 
research on PD-related stigma.  
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Younger age was related to increased perception of stigma in men with PD. The 
experience of diagnosis of a neurodegenerative disease relatively early in life may be 
qualitatively different than diagnosis in later life, having a greater impact on self-
perception and self-expectations in family, social, and occupational roles (Calne, 
Lidstone, & Kumar, 2008). Younger age of PD onset is associated with greater 
experience of motor complications such as dyskinesias and dystonia and with motor 
fluctuations (Bhidayasiri & Truong, 2008; Schrag & Schott, 2006; Wickremaratchi, Ben-
Shlomo, & Morris, 2009). The physical manifestations of these symptoms are 
challenging to conceal. Further, these symptoms can be unpredictable and uncontrollable, 
which may have emotional consequences such as anxiety and depression (Bhidayasiri & 
Truong, 2008) beyond the mood disturbances that are endogenous to the disease. Motor 
symptoms may also limit occupational capacity (Schrag et al., 2003; Schrag & Schott, 
2006), with poorer support in the workplace and greater symptom severity related to 
occupational impairment and unemployment (Banks & Lawrence, 2006). In addition to 
occupational challenges, PD symptoms limit the capacity to manage other aspects of 
daily living, such as driving, which is in conflict with the role expectations of younger 
individuals in particular (Schrag & Schott, 2006). Besides the physical and functional 
consequences of PD, which themselves are stigmatizing, younger age of PD onset is 
associated with depression (Calne et al., 2008; Schrag et al., 2003; Schrag & Schott, 
2006). Together, the burden of managing PD at a younger age is associated with multiple 
consequences that differentiate them from the societal norm, and may ultimately promote 
stigma. Although age did not predict stigma perception in women in our sample, further 
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research should consider whether gender differences arise for individuals who experience 
an even younger age of PD onset, as our sample was restricted to individuals who were 
age 40 and above at time of diagnosis.  
The significant impact of depression on stigma perception has important 
implications for conceptualizing stigma in PD and its potential treatment targets. In this 
study, depression was the strongest predictor of stigma and fully mediated the relation 
between ADLs and stigma. A similar pattern was demonstrated for the relation between 
the MDS-UPDRS motor score and depression, whereby depression accounted for a 
significant portion of the total effect, though the total effect was not significant (p = .07). 
Age, however, was not a significant mediator: the relation of stigma to motor symptoms 
and ADLs was not significantly influenced by age. Further, there was no difference in 
stigma perception for those categorized as having TD vs PIGD motor symptoms. 
Together, these results suggest that PD motor symptoms and their impact on daily life 
have relatively little contribution to the experience of stigma outside of the mediating role 
of depression. 
The emotional responses to the symptoms and challenges of PD may instead be 
the primary mechanisms of stigma in PD. This suggests that treatments focused entirely 
on alleviating motor symptoms that do not target the emotional response to PD will not 
alleviate stigma perception. For people with epilepsy, stigma has a negative relation to 
self-esteem, self-efficacy, and a sense of mastery, and has a positive relation with 
perceived helplessness, anxiety, and depression (Jacoby et al., 2005). The same may 
occur for PD – since depression is marked by feelings of helplessness and hopelessness, 
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the experience of PD may promote poorer self-esteem and self-efficacy (reduced belief in 
the controllability of the disease), thereby enhancing feelings of depression. The motor 
limitations of PD may affect the ability to conduct even basic activities of daily living, 
and individuals with PD often retain insight into this failure, possibly for decades as the 
disease progresses. Future research can distinguish between whether this emotional 
response is a perceived reaction to PD symptoms (e.g., a sense of uncertainty or 
helplessness toward PD, feelings of failure toward attaining role expectations) or whether 
this emotional response is a reaction to actual barriers (physical, occupational, social) 
imposed by PD.  
Our results provide direction for further investigation of mechanisms and 
treatment targets. Awareness of the burden of age and depression may prove particularly 
useful for providers, caregivers, and persons with PD themselves. Mood disorders in PD 
are commonly underdiagnosed (Pontone et al., 2009; Prediger et al., 2012), and untreated 
depression is associated with poorer quality of life (Shulman et al., 2002). Although 
motor dysfunction is a source of stigma, treating motor dysfunction without also targeting 
mood disturbance could be a major disservice to individuals with PD who experience 
stigma. Accordingly, treatments directed toward self-efficacy, positive appraisals, and 
behavioral activation may prove particularly beneficial to daily function. Previous 
research, unrelated to PD, has indicated that self-perception of illness and its effect on 
personal identity can impact the ability to cope and manage an illness (Charmaz, 1991; 
Soundy, Liles, Stubbs, & Roskell, 2014). This may be particularly relevant in PD, where 
motor limitations can interact with self-perception and affect quality of life. Whether 
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mood interventions can independently improve motor function and activities of daily 
living is an important question for future research. Improvements in self-perceived stigma 
have been reported to follow neurosurgical treatments targeted toward motor function 
(Deuschl et al., 2006; Williams, Gill, et al., 2010), but the degree to which these 
improvements are mediated by improved mood has not been established. Without 
recognizing the impact of mood on functional outcomes in PD, the conceptualization and 
treatment of PD motor limitations may be incomplete.  
This study was subject to limitations. First, we found that only 14.5% of the 
variance in stigma was accounted for by the regression model, suggesting that other 
variables also account for stigma perception in PD. Second, other scales designed 
specifically for assessing stigma may offer a more thorough description of this 
phenomenon in PD than the stigma measure used in the present study (PDQ-39), which 
was limited to four items. Using another stigma scale with more items may yield greater 
variability in responses and allow for a more robust assessment of variance in PD stigma 
perception. Finally, our study excluded individuals with PD onset before the age of 40 
and individuals who received neurosurgical treatment for PD. Assessing stigma in these 
PD subgroups may offer additional insight into underlying mechanisms and correlates, 
and may be particularly important to evaluating our finding that stigma perception is 
especially heightened in earlier-onset PD.  
In conclusion, the results of this study inform the subjective experience of PD, 
highlighting the non-motor symptom of depression in the experience of stigma. Though 
PD is primarily characterized by motor dysfunction, the outward physical limitations of 
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PD may drive stigma less than the subjective and emotional burden of managing PD. 
These results support a patient-centered approach to PD treatment (van der Eijk, Nijhuis, 
Faber, & Bloem, 2013), which considers how demographic characteristics such as age 
may interact with PD motor limitations and promote stigma perception and depression. 
Interventions that target mood may have greater efficacy in improving stigma than motor 
treatments alone, and may be critical to improving quality of life.  
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Tables and Figures 
Table 13 
Participant Characteristics 
 Age 
(years) 
PD 
Duration 
(years) 
MDS-
UPDRS 
Part 2 
(ADL) 
MDS-
UPDRS 
Part 3 
(Motor) 
GDS 
(N=348) 
PDQ-
39Stigma 
LED 
(mg/day) 
(N=360) 
Mean 
(SD)  
67.0 
(8.8) 
6.1 
(4.7) 
12.7 
(7.5) 
32.2 
(14.6) 
7.3 
(5.4) 
14.9 
(17.6) 
652.0 
(556.8) 
 
PD = Parkinson’s disease; MDS-UPDRS = Movement Disorders Society Unified 
Parkinson’s Disease Rating Scale; ADL = Activities of Daily Living; GDS = Geriatric 
Depression Scale; PDQ-39 = 39-item Parkinson’s Disease Questionnaire; LED = 
Levodopa equivalent dosage; SD = standard deviation; Unless otherwise indicated, the 
sample size for all variables was 362 (157 women, 205 men). The numbers of 
participants categorized as tremor dominant (TD), postural instability and gait disorder 
(PIGD), indeterminate (IND) were 110, 223, 29, respectively. MDS-UPDRS values 
reflect the on-medication state. 
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Table 14 
Mediation Analyses 
Model 1 Predictor:  UPDRS-ADL DV: Stigma Mediator: GDS   
  Path B SE T P 95% CI 
  a 0.36 0.04 9.13 <.0001 0.28, 0.43 
 b 0.93 0.23 4.14 <.0001 0.49, 1.38 
total effect c 0.49 0.15 3.37 0.0008 0.20, 0.77 
direct effect c - (a*b) 0.16 0.14 1.11 0.27 -0.12 ,0.44 
indirect effect c' 0.33 0.10     0.18, 0.56 
 
Model 2 Predictor:  UPDRS-Motor DV: Stigma Mediator: GDS   
  Path B SE T P 95% CI 
  a 0.14 0.02 7.73 <.0001 0.11, 0.18 
  b 1.05 0.27 4.86 <.0001 0.63, 1.48 
total effect c 0.14 0.08 1.79 0.07 -0.01, 0.30 
direct effect c - (a*b)     -0.01 0.08     -0.11 0.92 -0.16, 0.14 
indirect effect c' 0.15 0.04    0.09, 0.25 
 
Model 3 Predictor:  UPDRS-ADL DV: Stigma Mediator: Age 
 
  Path B SE T P 95% CI 
  a 0.21 0.06 3.46 0.0006 0.09, 0.33 
  b     -0.37 0.12     -2.98 0.0031 -0.61, -0.13 
total effect c 0.51 0.14 3.58 0.0003 0.23, 0.80 
direct effect c - (a*b) 0.59 0.15 4.04 <.0001 0.30, 0.88 
indirect effect c'     -0.08 -0.03     -0.16, -0.03 
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Model 4 Predictor:  UPDRS-Motor DV: Stigma Mediator: Age   
  Path B SE T P 95% CI 
  a 0.15 0.04 4.15 <.0001 0.08, 0.23 
  b     -0.37 0.14     -2.71 0.007 -0.64, -0.10 
total effect c 0.16 0.08 2.00 0.046 0.003, 0.31 
direct effect c - (a*b) 0.21 0.08 2.63 0.009 0.05, 0.37 
indirect effect c'     -0.06 0.02     -0.11, -0.03 
 
UPDRS-ADL = Unified Parkinson’s Disease Rating Scale Activities of Daily Living Section; 
UPDRS-Motor = Unified Parkinson’s Disease Rating Scale Motor Section; DV = dependent variable; 
B = unstandardized regression coefficient; SE = Standard Error; t = t-value; 95% CI = 95% confidence 
interval 
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Figure 5 
Depression mediates MDS-UPDRS ADLs and PDQ-39stigma 
 
Direct effect: B = .16, 95% CI: -.12, .44 
UPDRS ADLs = Unified Parkinson’s Disease Rating Scale Activities of Daily                
Living Section 
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CHAPTER 6: GENERAL DISCUSSION 
 
The purpose of this project was to assess the interaction of motor and non-motor 
symptoms that commonly present in PD and directly affect quality of life. The individual 
studies considered how motor and non-motor symptoms contribute to walking, spatial 
judgment, self-reported anxiety, and self-perceived stigma. Each study revealed 
interactions between motor and non-motor symptoms that may be easily overlooked 
under traditional assessment and intervention practices. 
The results of these studies encourage continued research of these interactive 
motor-non-motor symptoms. In doing so, novel treatment targets and assessment tools 
may be developed and implemented. Though traditionally considered a motor disease or 
a movement disorder, the hallmark motor limitations of PD should not be divorced from 
PD’s pervasive non-motor symptoms. For example, limits to the ability to engage in 
activities of daily living may be most readily attributed to visible motor symptoms 
(tremor, gait, etc.), but may be compounded by motivational, emotional, cognitive, and 
visual disturbances. Until the full extent of these symptoms is recognized, the capacity to 
maximize quality of life for individuals with PD will necessarily be limited. It is 
important to note that the observations and conclusions of this project occurred within the 
scope of a tightly controlled laboratory setting with high functioning individuals with PD; 
nevertheless, the consequences of the combined motor and non-motor burden of PD were 
apparent. In less controlled settings, and with more severe disease stages, these 
interactive effects may be even more likely to occur.  
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Study 1 focused on gait, which is commonly impacted by PD. Classic reductions 
of walking speed and changes in stride frequency were observed when individuals with 
PD were confronted with a dual task. This study was one of the first to demonstrate that 
executive functioning (set-shifting) is also impacted by dual tasking. Not only did 
individuals with PD produce fewer set-shifts on dual tasking than NC, they also 
demonstrated an increased inter-trial variability, which suggests an inconsistency in their 
cognitive output. The deficits observed on dual tasking were in a high functioning, 
medicated PD group. Even for this group that was receiving standard care for PD, motor 
deficits still occurred when faced with cognitive burden, suggesting that opportunities 
remain for considering alternate avenues for preserving and improving gait function in 
PD. Study 1 provided support for considering the cognitive contributors to locomotion, 
and suggested a treatment option beyond standard pharmacological interventions for PD 
motor symptoms. By targeting cognition, individuals with PD may more competently 
compensate for the burden of motor-related gait deficits. Considering that more severe 
gait impairments, such as freezing of gait, can be resistant to some pharmacological 
interventions (Nonnekes et al., 2015; Schaafsma et al., 2003), a cognitive intervention 
may offer a novel avenue for improving these problems with locomotion. In light of the 
present results, future research might consider how targeting sustained attention and set-
shifting might translate into improved gait in PD. Our PD sample showed a specific 
reduction in set-shifting on dual task, while also showing increased cognitive variability, 
which may suggest that individuals with PD may inefficiently allocate attentional and 
executive resources while walking. This aligns with the automaticity deficits intrinsic to 
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PD – since individuals with PD experience limited automaticity in the execution of motor 
movements, there is a heightened necessity to consciously allocate attentional and 
executive resources in order to compensate. Within this context, there is a high likelihood 
that individuals with PD may struggle to effectively allocate cognitive resources to the 
multiple demands of walking. Further burdens may exist, such as limits to perception and 
visuospatial function (Almeida et al., 2005; Nantel et al., 2012; Ren et al., 2015), or 
emotional stress such as anxiety (Martens, Ellard, & Almeida, 2014), which may further 
contribute to gait problems. Future research can consider these multifaceted aspects of 
gait problems in PD. 
Study 2 explored the mechanisms of spatial bias in PD and supported the 
contribution of higher-order executive function to spatial bias in PD. This aligns with 
existing evidence that has failed to observe an effect of lower-order perceptual 
contributions to spatial bias (Laudate et al., 2013; Norton, Jaywant, Gallart-Palau, & 
Cronin-Golomb, 2015). Unlike the traditional hemineglect that occurs in individuals with 
parietal injury, the spatial bias of PD is more subtle, and seems to be related to fronto-
striatal dysfunction, at least for the task used in the present study. This was the largest 
study to date of spatial bias in PD in regard to sample size, and offers important avenues 
for future research and treatment. If errors in spatial judgment in PD are driven by 
frontal-attentional deficits, this may be a promising target of cognitive intervention. The 
consequences of spatial bias in daily life remain largely unexplored, and future 
investigations may identify targets to reduce the functional barriers that are caused by 
spatial bias in PD. Consistent with the theme of Study 1, if spatial bias is driven by 
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attentional-executive deficits, training tailored toward to the effective allocation of 
cognitive resources may provide means of compensating for errors in spatial judgment. In 
a sense, spatial judgment may itself be a form of dual tasking in PD – since individuals 
with PD are burdened with the demands of directing attention to “primary” motor 
movements, cognitive resources may not be fully allocated to other “secondary” non-
motor tasks (e.g., spatial judgment). Training individuals with PD to recognize and 
manage simultaneous motor-non-motor tasks may promote better accuracy in spatial 
judgment. 
Study 3 investigated the impact of motor symptoms on self-reported mood. The 
results indicated that motor items group together on the BAI, and that these symptoms 
significantly accounted for PD-NC differences on this measure. Nonetheless, when these 
motor symptoms were accounted for, PD continued to endorse more anxiety than NC, 
which suggests that the BAI is to some extent measuring meaningful mood dysfunction 
in PD. These results provide implications for measuring mood in PD. The BAI is very 
commonly used in the clinic and the research lab, despite its lack of validation in PD. 
This longstanding oversight is evidence of a proclivity toward overlooking the 
complexities of interactive motor and non-motor symptoms in PD. The urgency of 
employing PD-specific mood measures is heightened by the growing awareness that 
mood has a substantial impact on quality of life, and that mismanagement of mood 
symptoms could negatively impact quality of life. For example, pharmacological 
interventions for PD are associated with unwanted side effects (Antonini & Cilia, 2009; 
Smith, Wichmann, Factor, & DeLong, 2012) that may have a negative impact on quality 
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of life. Study 3 demonstrated that the BAI may overestimate anxiety in PD and further 
highlights the questionable construct validity of the BAI in PD (i.e., the BAI may not 
only be assessing the construct of “anxiety”, but may also measure other constructs such 
as motor symptoms). That this effect occurred in a high functioning PD sample without a 
history of diagnosed mood disorders raises concern when considering potential 
mismanagement of mood symptoms for individuals with more severe PD. Although 
clinicians and researchers may be aware of these limitations and may attempt to filter 
responses to accurately reflect anxiety, there remains much risk of misrepresenting and 
misinterpreting mood symptoms. For example, a clinician might inform an individual 
with PD not to endorse an item on the BAI if it is specifically a PD motor symptom. This 
assumes that motor and mood symptoms are always mutually exclusive, which may not 
be the case. Anxiety may reduce motor control, or visible motor symptoms may promote 
anxiety. Without a PD-specific anxiety measure, the ability to accurately draw 
conclusions about anxiety is limited. The recent development of the PD-specific 
Parkinson Anxiety Scale (Leentjens et al., 2014) is a promising step toward improving 
the assessment and treatment of anxiety in PD, however, it remains to be seen if this 
measure will be widely used by clinicians and researchers. Continued work on 
determining the barriers to employing PD-specific assessments may be an effective 
avenue toward improving the standard of care for individuals with PD.  
Study 4 highlighted the factors that contribute to self-perceived stigma in PD. 
This study is one of the first to quantify stigma in PD, and is to date, the largest study of 
self-perceived stigma in PD in regard to sample size. For both men and women, 
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depression was the most significant predictor of self-perceived stigma. For men, younger 
age was also a significant predictor. Contrary to expectations, disease characteristics such 
as motor symptom subtype did not significantly contribute to stigma, nor was stigma 
perception significantly different between men and women. The results of this study 
suggest that specific, visible features of PD (e.g., tremor) are less critical to stigma than 
are the emotional challenges in PD. The fact that depression had the greatest contribution 
to stigma raises promising targets for future research and treatment. Study 4 suggests that 
depression may be an important mechanism of self-perceived stigma in PD. Negative 
attributions may be a common link between overlapping depression and stigma – the 
specific mechanisms may be elucidated by further research. Treatments that target 
depression or employ techniques common in depression treatment may provide relief 
from self-perceived stigma in PD.  
Several questions remain unanswered by Study 4. The prevalence of self-
perceived stigma in PD and its impact on quality of life remains undefined. The nature of 
this study, and the stigma measure employed, precluded the ability to define stigma’s 
prevalence and impact. Understanding the prevalence and impact of stigma will be 
critical to advocating for its assessment and treatment. The widespread popularity of PD 
support groups seems to suggest that mutual support for managing PD is valuable, 
possibly because of the complicated and stigmatizing features of PD. There is a dearth of 
research exploring stigma in PD, and there is great potential for meaningful advocacy 
with the advance of quantitative research efforts. Another question that remains 
unanswered by Study 4 is whether PD motor symptoms in fact predict stigma in PD. This 
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relatively high functioning sample may not fully represent the variety of stigmatizing 
experiences present across the disease spectrum. Further, the stigma scale used in this 
study (just four items from the PDQ-39) may have lacked the power to fully detect the 
complexities of motor dysfunction in PD. Future research should employ additional 
stigma measures to better capture a wider range of stigmatizing experiences in PD, and to 
consider which motor symptoms most contribute to stigma. It is reasonable to 
hypothesize an interaction between demographic and motor symptoms, such that 
individuals who are most severely in violation of social norms (e.g., younger age, 
women), may be particularly affected by visible motor symptoms such as tremor, 
dyskinesia, and facial masking.  
PD has a pervasive impact on many aspects of daily living, and this calls for 
careful consideration of how to best provide care that not only alleviates obvious motor 
symptoms, but the entire range of PD symptoms. Individuals with PD may survive for 
decades with relatively intact independence and insight, and failure to provide services 
that are sensitive to PD’s disease course may be a tragic oversight of current practices. 
The substantial alterations to occupational, social, and family roles highlights the 
importance of providing multifaceted means for maximizing quality of life across the 
disease course. Failure to recognize these unique facets of PD renders the assessment and 
intervention of PD symptoms incomplete.  
In all, these studies demonstrate the consequences of interactive motor and non-
motor symptoms in PD. The impact of PD on gait, spatial bias, anxiety, and stigma have 
all been previously documented, but these studies specifically consider how motor and 
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non-motor symptoms interact to promote dysfunction in PD. Further, the sample sizes 
used to study spatial bias and stigma are the largest sample sizes to date. Future research 
can continue to elucidate the complex symptomatology of PD and the many variables that 
may contribute to symptom presentation and quality of life. The results of these studies 
demonstrated how demographic characteristics such as age and gender are relevant in the 
symptom presentation and experience of PD; other factors, such as the interaction of age 
and gender, socioeconomic status, and social support, may be worthwhile avenues of 
future consideration. Further, these studies demonstrated that the complex symptom 
presentation of PD can also impact the measurement of non-motor symptoms, such as 
self-reported anxiety. Continued work can address other ways in which the measurement 
of PD symptoms may be confounded by specific PD symptoms. The heterogeneity of PD 
presents many challenges to accurately managing the disease; this heterogeneity has 
prompted efforts to consider a more individualized and targeted approach to treating PD 
(Berg et al., 2014). Together, the results of this set of studies suggest potential avenues 
for enhancing the measurement, diagnosis, and treatment of PD.   
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